

Curriculum Vitae for: Benjamin M. Craig, Ph.D.
Date: 01 January 2025

**Current Academic
Appointment:**

Associate Professor [Adjunct]
Department of Economics
University of South Florida
4202 E. Fowler Avenue, CMC206A
Tampa, Florida, USA 33620
bcraig@usf.edu
Phone: (404) 436-0659

Education

2003 Ph.D. Population Health, University of Wisconsin-Madison, Madison, Wisconsin, USA
1999 M.A. Economics, University of Texas at Austin, Austin, Texas, USA
1995 B.A. Economics, University of Wisconsin-Madison, Madison, Wisconsin, USA

Academic Appointments and Employment

2007-Present **Associate Professor** [Adjunct], Department of Economics, University of South Florida, Tampa, Florida, USA
2021-2022 **Visiting Scholar**, Nuffield Department of Population Health, University of Oxford, Oxford, UK
2013-2016 **Associate Professor [tenured]**, Department of Oncologic Sciences, College of Medicine, University of South Florida, Tampa, Florida, USA
2013-2016 **Associate Member**, Health Outcomes & Behavior, Division of Population Science, Moffitt Cancer Center, Tampa, Florida, USA
2007-2013 **Assistant Professor [tenure-track]**, Department of Oncologic Sciences, College of Medicine, University of South Florida, Tampa, Florida, USA
2007-2013 **Assistant Member**, Health Outcomes & Behavior, Division of Population Science, Moffitt Cancer Center, Tampa, Florida, USA
2011 **Visiting Scholar**, Health Economics Research Unit, Division of Applied Health Sciences, College of Life Sciences and Medicine, University of Aberdeen, Aberdeen, Scotland, UK
2009 **Visiting Scholar**, Health Economics and Decision Sciences, School of Health and Related Research, University of Sheffield, Sheffield, England, UK
2006-2007 **Visiting Assistant Professor**, Department of Family Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA
2005-2006 **Visiting Scholar**, Sonderegger Research Center, School of Pharmacy, University of Wisconsin, Madison, Wisconsin, USA
2003-2006 **Assistant Professor [tenure-track]**, Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, Arizona, USA
2003-2006 **Associate Investigator**, Arizona Cancer Center, Arizona Health Sciences Center, University of Arizona, Tucson, Arizona, USA
1999-2003 **AHRQ Pre-doctoral Trainee**, Department of Population Health Sciences, Medical School, University of Wisconsin-Madison, Madison, Wisconsin, USA
1996-1999 **Graduate Research and Teaching Assistant**, Department of Economics, College of Arts and Sciences, University of Texas at Austin, Austin, Texas, USA
1995-1996 **Research Fellow**, Department of Applied and Agricultural Economics, College of Agricultural and Life Sciences, University of Wisconsin-Madison, Madison, Wisconsin, USA

Teaching Experience

University Courses:

Fall 2025	Guest Speaker: <u>Stakeholder Preference Elicitation and Decision Support</u> , University of Twente, Enschede, the Netherlands
Spring 2021	Instructor: <u>Econometrics III</u> (ECO7426), University of South Florida, Tampa, Florida, USA
Fall 2019	Instructor/Coordinator: <u>Econometrics Study Group in R</u> (independent study), University of South Florida, Tampa, Florida, USA
Spring 2017	Instructor/Coordinator: <u>Economics of Health</u> (ECP3530), University of South Florida, Tampa, Florida, USA Guest Speaker: <u>Pharmaceutical Economics</u> , University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
Spring 2016	Instructor: <u>Economics of Health</u> (ECP3530), University of South Florida, Tampa, Florida, USA
Fall 2015	Instructor: <u>Economics of Health Care</u> (ECP6536), University of South Florida, Tampa, Florida, USA
Fall 2013	Instructor: <u>Economics of Health Care</u> (ECP6536), University of South Florida, Tampa, Florida, USA
Spring 2013	Guest Speaker: <u>Health Economics II</u> (PubH 6832), University of Minnesota, Minneapolis, Minnesota, USA
Fall 2005	Instructor/Coordinator: <u>Health Technology Assessment</u> (PhSc513), University of Arizona, Tucson, Arizona, USA
Fall 2005	Instructor/Coordinator: <u>Medication Use and the U.S. Health Care System</u> (PhPr 445), University of Arizona, Tucson, Arizona, USA
Spring 2005	Guest Speaker: <u>Applied Health Technology Assessment</u> (PhSc 613), University of Arizona, Tucson, Arizona, USA
Fall 2004	Instructor/Coordinator: <u>Health Technology Assessment</u> (PhSc 513), University of Arizona, Tucson, Arizona, USA
Fall 2004	Instructor/Coordinator: <u>Medication Use and the U.S. Health Care System</u> (PhPr 445), University of Arizona, Tucson, Arizona, USA
Summer 2004	Instructor/Coordinator: <u>Introduction to Microeconomic Theory</u> (PhSc 599), University of Arizona, Tucson, Arizona, USA
Spring 2004	Guest Speaker: <u>Applied Health Technology Assessment</u> (PhSc 613), University of Arizona, Tucson, Arizona, USA
Fall 2003	Guest Speaker: <u>Professional Practice Management</u> (PhPr 442), University of Arizona, Tucson, Arizona, USA
Fall 2003	Guest Speaker: <u>Health Technology Assessment</u> (PhSc 513), University of Arizona, Tucson, Arizona, USA
Fall 2003	Instructor: <u>Medication Use and the U.S. Health Care System</u> (PhPr 445), University of Arizona, Tucson, Arizona, USA

Other Courses and National Symposia

Instructor/Coordinator:

2023	Introduction to the Design & Database Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources, ISPOR 2023, Boston, Massachusetts, USA, May 7, 2023 (workshop).
2022	Introduction to latent class analysis, Online, EuroQol Research Foundation, Rotterdam, the Netherlands, June 10- 2022 (workshop)

- Introduction to the Design & Database Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources, ISPOR 2022, Washington, District of Columbia, USA, May 15, 2022 (workshop).
- 2019 Good Practices in Health Preference Research, International Academy of Health Preference Research, 11th Meeting, Auckland, New Zealand, December 2, 2019 (workshop).
Health Preference Research: past, present and possible future, International Society for Pharmacoeconomics and Outcomes Research, Student Chapter Meeting, Singapore, November 11, 2019 (workshop).
Use of Instrumental Variables in Observational Studies of Treatment Effects, National University of Singapore, November 11, 2019 (workshop).
Psychology of Marketing, Consumer Psychology (160 students), Universitas Padjadjaran, Bandung, Indonesia, November 13, 2019.
Health Preference Research: past, present and possible future, Good Practices in Health Preference Research, Faculty Seminar, Universitas Padjadjaran, Bandung, Indonesia, November 13, 2019.
Use of Instrumental Variables in Observational Studies of Treatment Effects, International Society for Pharmacoeconomics and Outcomes Research, 24th Annual Meeting, New Orleans, Louisiana, USA, May 19, 2018 (workshop).
Introduction to the Design & Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources, International Society for Pharmacoeconomics and Outcomes Research, 24th Annual Meeting, New Orleans, Louisiana, USA, May 18, 2018 (workshop).
- 2018 Use of Instrumental Variables in Observational Studies of Treatment Effects, International Society for Pharmacoeconomics and Outcomes Research 21th Annual European Congress, Barcelona, Spain, November 11, 2018 (workshop).
Use of Instrumental Variables in Observational Studies of Treatment Effects, International Society for Pharmacoeconomics and Outcomes Research, 23rd Annual Meeting, Baltimore, Maryland, USA, May 20, 2018 (workshop).
Introduction to the Design & Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources, International Society for Pharmacoeconomics and Outcomes Research, 23rd Annual Meeting, Baltimore, Maryland, USA, May 19, 2018 (workshop).
- 2017 Use of Instrumental Variables in Observational Studies of Treatment Effects, International Society for Pharmacoeconomics and Outcomes Research 20th Annual European Congress, Glasgow, Scotland, November 2, 2017 (workshop).
Use of Instrumental Variables in Observational Studies of Treatment Effects, International Society for Pharmacoeconomics and Outcomes Research, 22nd Annual Meeting, Boston, Massachusetts, USA, May 20, 2017 (workshop).
Introduction to the Design & Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources, International Society for Pharmacoeconomics and Outcomes Research, 22nd Annual Meeting, Boston, Massachusetts, USA, May 20, 2017 (workshop).
- 2016 Use of Instrumental Variables in Observational Studies of Treatment Effects, International Society for Pharmacoeconomics and Outcomes Research 19th Annual European Congress, Vienna, Austria, October 30, 2016 (workshop).
Use of Instrumental Variables in Observational Studies of Treatment Effects, International Society for Pharmacoeconomics and Outcomes Research, 21st Annual Meeting, Washington, District of Columbia, USA, May 21, 2016 (workshop).
- 2015 Use of Instrumental Variables in Observational Studies of Treatment Effects, International Society for Pharmacoeconomics and Outcomes Research, 18th Annual European Congress, Milan, Lombardy, Italy, November 8, 2015 (workshop).
Instrumental Variables in Addressing Selection Bias in Observational Studies, International Society for Pharmacoeconomics and Outcomes Research, 20th Annual Meeting, Philadelphia, Pennsylvania, USA, May 17, 2015 (workshop).

- QALYs in Cost-Effectiveness and Benefit-Cost Analysis: How to be an Informed Consumer, Society for Benefit-Cost Analysis, Washington, District of Columbia, USA, March 18, 2015 (workshop).
- 2014 Discrete Choice Experiments: Enhancing PRO beyond QALY, Centre for Health Economics, Monash University, Clayton, Victoria, Australia, November 28, 2014 (workshop).
Use of Instrumental Variables in Observational Studies of Treatment Effects, International Society for Pharmacoeconomics and Outcomes Research, 17th Annual European Congress, Amsterdam RAI, Amsterdam, the Netherlands, November 9, 2014 (workshop).
Discrete Choice Experiments: Enhancing PRO beyond QALYs, International Society for Quality of Life Research, 21st Annual Conference, Berlin, Germany, October 15, 2014 (course).
Discrete Choice Experiments on HRQoL: Enhancing PRO beyond QALYs, QALY Brazil, Rio de Janeiro, Brazil, March 13, 2014 (course).
Instrumental Variables in Addressing Selection Bias in Observational Studies, International Society for Pharmacoeconomics and Outcomes Research, 19th Annual Meeting, Palais des Congrès de Montréal, Montreal, Quebec, Canada, June 1, 2014 (course).
- 2013 Instrumental Variables in Addressing Selection Bias in Observational Studies, International Society for Pharmacoeconomics and Outcomes Research, 16th Annual European Congress, The Convention Center Dublin, Dublin, Ireland, November 3, 2013 (course).
Discrete Choice Experiments: Enhancing PRO beyond QALYs, International Society for Quality of Life Research, 20th Annual Conference, Miami, Florida, USA, October 9, 2013 (course).
Instrumental Variables in Addressing Selection Bias in Observational Studies, International Society for Pharmacoeconomics and Outcomes Research, 18th Annual Meeting, New Orleans, Louisiana, USA, May 19, 2013 (course).
Introduction to Database Analysis of Observational Studies of Treatment Effects, International Society for Pharmacoeconomics and Outcomes Research, 18th Annual Meeting, New Orleans, Louisiana, USA, May 18, 2013 (course).
- 2012 Instrumental Variables in Addressing Selection Bias in Observational Studies, International Society for Pharmacoeconomics and Outcomes Research, 15th Annual European Congress, ICC Berlin, Berlin, Germany, November 4, 2012 (course).
Instrumental Variables in Addressing Selection Bias in Observational Studies, International Society for Pharmacoeconomics and Outcomes Research, 17th Annual Meeting, Washington Hilton, Washington, District of Columbia, USA, June 1, 2012 (course).
- 2011 Online Experimental Techniques, Moffitt Cancer Center, Tampa, Florida, USA, May 5, 2011 (workshop).
- 2010 Instrumental Variables in Addressing Selection Bias in Observational Studies, International Society for Pharmacoeconomics and Outcomes Research, 15th Annual Meeting, Atlanta, Georgia, USA, May 15, 2010 (course).
- 2009 Instrumental Variables in Addressing Selection Bias in Observational Studies, International Society for Pharmacoeconomics and Outcomes Research, 14th Annual Meeting, Orlando, Florida, USA, May 16, 2009 (course).
- 2008 Instrumental Variables in Addressing Selection Bias in Observational Studies, International Society for Pharmacoeconomics and Outcomes Research, 13th Annual Meeting, Toronto, Ontario, Canada, May 3, 2008 (course).
Instrumental Variables in Addressing Selection Bias in Observational Studies, Moffitt Cancer Center, Tampa, Florida, USA, February 28, 2008 (workshop).
- 2007 Basics of Statistics, Fellows Research Conference, University of Wisconsin, Department of Nephrology, Madison, Wisconsin, USA, October 24, 2007 (course).
Instrumental Variables in Addressing Selection Bias in Observational Studies, International Society for Pharmacoeconomics and Outcomes Research, 12th Annual Meeting, Arlington, Virginia, USA, May 19, 2007 (course).

Teaching and Training Experience

Graduate Training:

2024-present	Jelke te Focht, Health Technology and Services Research, Department of Technology, Policy and Society, University of Twente, Enschede, the Netherlands. Served as external advisor on Masters thesis and currently mentoring.
2020-2024	Maksat Jumamyradov, Department of Economics, University of South Florida, Tampa, Florida, USA. Served as co-chair on dissertation committee and mentored for 5 years.
2018-2022	Suzana Karim, Department of Economics, University of South Florida, Tampa, Florida, USA. Served as co-chair on dissertation committee and mentored for 5 years.
2021	Md Shahjahan, Department of Economics, University of South Florida, Tampa, Florida, USA. Mentored in my lab for 1 semester.
2016-2020	Stephen Poteet, Department of Economics, University of South Florida, Tampa, Florida, USA. Served as co-chair on dissertation committee and mentored for 5 years.
2014-2018	John Hartman, Department of Economics, University of South Florida, Tampa, Florida, USA. Served as co-chair of Dissertation Committee and mentored for 5 years.
2015-2016	Edson Santoro, Department of Economics, University of South Florida, Tampa, Florida, USA. Mentored in my lab for 1 year.
2009-2016	Shannon Runge, Aging Studies Program, University of South Florida, Tampa, Florida, USA. Mentored in my lab for 7 years.
2014-2015	Kathleen McFadden, College of Medicine, University of South Florida, Tampa, Florida, USA. Mentored in my lab for 1 year.
2010-2013	Larry Kessler, Department of Economics, University of South Florida, Tampa, Florida, USA. Served as member of Dissertation Committee and mentored for 3 years.
2012-2013	Berna Colak, Department of Economics, University of South Florida, Tampa, Florida, USA. Mentored in my lab for 1 year.
2009-2011	Andrea Collado, Department of Economics, University of South Florida, Tampa, Florida, USA. Mentored in my lab for 2 years.
2008-2009	Taiwo Abimbola, Department of Economics, University of South Florida, Tampa, Florida, USA. Mentored in my lab for 2 years.
2008	Melissa Mugharbel, Department of Economics, University of South Florida, Tampa, Florida, USA. Mentored in my lab for 1 year.
2003-2006	Sulabha Ramachandran, Department of Pharmacy Practice and Science, University of Arizona, Tucson, Arizona, USA. Served as member of Masters and Dissertation Committees.
2003-2006	J. Jason Lundy, Department of Pharmacy Practice and Science, University of Arizona, Tucson, Arizona, USA. Served as member of Masters Committee.

Student Advising:

2024-present	Minh Pham, University of South Florida, Tampa, Florida, USA. Currently mentoring.
2021-2022	Shotaro Okubo, University of South Florida, Tampa, Florida, USA. Mentored for 1 year.
2018-2019	Pelin Aroguz, University of South Florida, Tampa, Florida, USA. Mentored for 1 year.
2017-2017	Ryan Hagen, University of South Florida, Tampa, Florida, USA. Mentored for 1 year.
2015-2016	Raquel Cancho, University of South Florida, Tampa, Florida, USA. Mentored for 2 years.
2014-2016	Michael Stepanski, University of Miami, Coral Gables, Florida, USA. Mentored for 3 years.
2014-2016	Bianca T. Nguyen, University of South Florida, Tampa, Florida, USA. Mentored for 3 years.
2013-2016	Mazin Ibrahim, University of South Florida, Tampa, Florida, USA. Mentored for 4 years.
2013-2016	Nawreen Jahan, University of South Florida, Tampa, Florida, USA. Mentored for 4 years.
2012-2015	Catherine Blackburn, University of South Florida, Tampa, Florida, USA. Mentored for 4 years.
2012-2014	Mary Tomaino, University of South Florida, Tampa, Florida, USA. Mentored for 2 years.

2011-2013	Zein Kattih, University of South Florida, Tampa, Florida, USA. Mentored for 2 years.
2011-2013	Janel Phetteplace, University of South Florida, Tampa, Florida, USA. Mentored for 2 years.
2008-2011	Riddhi Patel, University of South Florida, Tampa, Florida, USA. Mentored for 3 years.
2009-2010	Ayesha Farooq, University of South Florida, Tampa, Florida, USA. Mentored for 2 years.

Honors and Awards

2011	Outstanding Faculty Performance in Basic and Population Science awarded by Moffitt Cancer Center.
2005-2006	Research Starter Grant in Health Outcomes awarded by Pharmaceutical Research and Manufacturers of America Foundation.

Research Support

Ongoing

Non-Profit Foundation Grants:

PI:	Craig, BM
Dates:	9/1/2024-9/1/2025
Source:	EuroQol Research Foundation
Title:	Assessing TIPS via Kaizen [1850-RA]
% Effort:	0%
Role in the Study:	Principal Investigator
Total Direct Costs:	€85.529,80
PI:	Craig, BM
Dates:	4/1/2024-4/1/2025
Source:	EuroQol Research Foundation
Title:	Valuing EQ-5D-5L+Cognition via Kaizen (VECK) [1769-RA]
% Effort:	0%
Role in the Study:	Principal Investigator
Total Direct Costs:	€59.644

Completed

Government Grants:

PI:	Craig, BM
Dates:	09/09/2011-06/30/2016
Source:	NCI
Title:	HRQoL Values for Cancer Survivors: Enhancing PROMIS Measures for CER [R01-CA160104]
% Effort:	10%
Role in the Study:	Principal Investigator
Total Direct Costs:	\$ 2,091,804
Total Amount of Award:	\$ 3,129,188
PI:	Brandon, TH
Dates:	04/01/2015-01/31/2020
Source:	NIDA

Title:	Smoking Cessation Self-Help for Dual Users of Tobacco Cigarettes and E-Cigarettes [R01-DA037961-01A1]
% Effort	3%
Role in the Study:	Co-Investigator Contributions include the proposal, design, conduct and publication of a cost-effectiveness study.
Total Direct Costs:	\$ 2,404,256
Total Amount of Award:	\$ 3,596,594
Grant Account:	
PI:	Meade, CD and Gwede, CK
Dates:	09/03/2010-08/31/2015
Source:	NCI
Title:	Tampa Bay Community Cancer Network Research Project: Colorectal Cancer Awareness, Research Education, and Screening [U54-CA153509]
% Effort:	2%
Role in the Study:	Co-Investigator Contributions include the proposal and advising on the design, conduct and publication of a cost-effectiveness study.
Total Direct Costs	\$ 1,314,327
Total Amount of Award:	\$ 2,194,926
PI:	Brandon, T
Dates:	05/11/2009-03/31/2014
Source:	NCI
Title:	Extended self-help for smoking cessation [R01-CA134347]
% Effort:	8%
Role in the Study:	Co-Investigator Contributions include the proposal, design, conduct and publication of a cost-effectiveness study.
Total Direct Costs:	\$ 2,060,340
Total Amount of Award:	\$ 3,440,768
PI:	Brandon, T
Dates:	01/01/2009-11/30/2012
Source:	NCI
Title:	Relapse-Prevention Booklets as Adjunct to a Tobacco Quitline
% Effort:	5%
Role in the Study:	Co-Investigator Contributions include the proposal, design, conduct and publication of a cost-effectiveness study [R01-CA137357]
Total Direct Costs:	\$ 1,786,846
Total Amount of Award:	\$ 2,808,995
PI:	Fenstermacher, D
Dates:	09/29/2009-08/31/2012
Source:	NCI
Title:	Developing Information Infrastructure Focused on Cancer Comparative Effectiveness Research [RC2-CA148332]
Effort:	5%

Role:	Co-Investigator Contributions include the proposal, administration, design, conduct and publication of a value of information study and 3 secondary data analysis of Medicare claims.
Total Direct Costs:	\$ 1,231,132
Total Amount of Award:	\$ 3,963,447
PI:	Craig, BM
Dates:	09/01/2006-08/31/2011
Source:	NCI
Title:	Obesity, Aging and Cancer Cost (OACC) Study [K25-CA122176]
% Effort:	75%
Role in the Study:	Principal Investigator
Total Direct Costs:	\$ 667,227
Total Amount of Award:	\$ 720,604
PI/Co-PI:	Jacobsen, P
Dates:	03/30/2009-08/31/2009
Source:	NCI
Title:	Moffitt Aging and Cancer Prevention Program [P20-CA103676]
% Effort:	8%
Role in the Study:	Co-Investigator
Total Direct Costs:	\$ 623,519
Total Amount of Award:	\$ 1,041,277
PI:	Lengacher, C
Dates:	09/22/2009-09/21/2010
Source:	NCI
Title:	MBSR Symptom Cluster Trial for Breast Cancer Survivors [R01-CA131080-01A2]
% Effort:	5%
Role in the Study:	Co-Investigator Contributions include the proposal and advising on the design, conduct and publication of a cost-effectiveness study.
Total Direct Costs:	\$ 593,504
Total Amount of Award:	Unknown
PI/Co-PI:	Babcock-Parziale, J
Dates:	04/01/2006-09/01/2006 [Withdrawn due to K-Award]
Source:	Veterans Affairs
Title:	Advancing Outcomes Measurement and Micro-costing in Blind Rehabilitation
% Effort:	20%
Role in the Study:	Co-Investigator Contributed to proposal and design of cost-effectiveness study.
Total Direct Costs:	Unavailable
Total Amount of Award:	\$ 508,053
Grant Account:	R03-HS013993
PI/Co-PI:	Craig, BM

Dates: 08/01/2003-07/31/2004 [withdrawn due to completion of dissertation]
Source: Agency for Healthcare Research and Quality
Title: Out-of-pocket Price, Prescription Drugs, and the Elderly
% Effort: 100%
Role in the Study: **Principal Investigator**
Total Direct Costs: \$ 30,000
Total Amount of Award: \$ 31,259

Non-Profit Foundation Grants:

PI: **Craig, BM**
Dates: 5/19/2022-5/18/2024
Source: EuroQol Research Foundation
Title: Acute and Chronic Episodes (ACE) Project
% Effort: 0%
Role in the Study: **Principal Investigator**
Total Direct Costs: € 42,780

PI: **Craig, BM**
Dates: 7/28/2021-8/01/2024
Source: EuroQol Research Foundation
Title: Sequential Relief of Child Health Problems
% Effort: 0%
Role in the Study: **Principal Investigator**
Total Direct Costs: € 102,718

PI: **Craig, BM**
Dates: 08/01/2021-07/30/2022
Source: EuroQol Research Foundation
Title: Introduction to Latent Classes in Health Valuation
% Effort: 0%
Role in the Study: **Principal Investigator**
Total Direct Costs: € 22,540

PI: **Craig, BM**
Dates: 01/01/2021-04/30/2022
Source: EuroQol Research Foundation
Title: Fast-Track Proposal: Scale, Rate, and Premium (SCRAP) in Health Valuation
% Effort: 0%
Role in the Study: **Principal Investigator**
Total Direct Costs: € 24,570

PI: **Craig, BM**
Dates: 8/1/2019-04/30/2022
Source: EuroQol Research Foundation
Title: Preference Heterogeneity in Health Valuation
% Effort: 0%
Role in the Study: **Principal Investigator**
Total Direct Costs: € 42,950

PI:	Craig, BM
Dates:	07/06/2020-02/31/2022
Source:	EuroQol Research Foundation
Title:	Preference Heterogeneity in Health Valuation: Dutch BWS Data
% Effort:	0%
Role in the Study:	Principal Investigator
Total Direct Costs:	€ 20,100
PI:	Craig, BM
Dates:	06/12/2020-02/31/2022
Source:	EuroQol Research Foundation
Title:	Preference Heterogeneity in Health Valuation: Peru EQ-VT Data
% Effort:	0%
Role in the Study:	Principal Investigator
Total Direct Costs:	€ 24,480
PI:	Craig, BM
Dates:	5/1/2017-2/27/2018
Source:	EuroQol Research Foundation
Title:	Exploring potential innovations in hybrid modeling
% Effort:	0%
Role in the Study:	Principal Investigator
Total Direct Costs:	€ 10,000
PI:	Craig, BM
Dates:	12/1/2016-3/27/2017
Source:	EuroQol Research Foundation
Title:	REDCap Evaluation: Instrument Construction
% Effort:	0%
Role in the Study:	Principal Investigator
Total Direct Costs:	€ 14,080
PI:	Craig, BM
Dates:	01/1/2016-6/2/2017
Source:	EuroQol Research Foundation
Title:	EQ DCE: Crowdsourcing innovation in valuation specification
% Effort:	0%
Role in the Study:	Principal Investigator
Total Direct Costs:	€ 116,132
PI:	Craig, BM
Dates:	06/1/2015-7/4/2016
Source:	EuroQol Research Foundation
Title:	The Effect of Timing, Duration, and Lifespan on Choice
% Effort:	0%
Role in the Study:	Principal Investigator
Total Direct Costs:	€ 68,439
PI:	Craig, BM

Dates: 07/1/2013-12/31/2013
Source: EuroQol Research Foundation
Title: The Relationship between Time, Sequencing and Precision
% Effort: 0%
Role in the Study: **Principal Investigator**
Total Direct Costs: \$ 32,253

PI: **Craig, BM**
Dates: 07/1/2013-12/31/2013
Source: EuroQol Research Foundation
Title: Preference Inversion in the EQ-5D-5L
% Effort: 0%
Role in the Study: **Principal Investigator**
Total Direct Costs: \$ 11,957
Total Amount of Award: \$ 11,957

PI: **Craig, BM**
Dates: 03/01/2009-2/28/2011
Source: International Papillomavirus Society
Title: Pre-Conference on Modeling Evidence in HPV
% Effort: 1%
Role in the Study: **Principal Investigator**
Total Direct Costs: \$ 200,000
Total Amount of Award: \$ 200,000

PI/Co-PI: **Goode, K**
Dates: 01/01/2007-12/31/2007
Source: Community Pharmacy Foundation
Title: Evaluating Pharmacy Immunization in Community Settings (EPICS)
% Effort: 0%
Role in the Study: **Co-Investigator**
Contributions include the proposal and design of a secondary data analysis of Medicare claims.
Total Direct Costs: Unavailable
Total Amount of Award: \$ 50,526

PI/Co-PI: **Craig, BM**
Dates: 01/01/2005-08/31/2006
Source: PhRMA
Title: Economic Burden of Cancer Borne by Patients, Medicare, and Other Payers, 1992-2001
% Effort: 10%
Role in the Study: **Principal Investigator**
Total Direct Costs: \$ 60,000
Total Amount of Award: \$ 60,000

Industry Grants:

Co-PI: **Craig, BM and Cogle, C**
Dates: 03/01/2010-12/31/2010
Source: Celgene

Title:	Pilot Study of SEER-Medicare Database to Define MDS Incidence
% Effort:	5%
Role in the Study:	Co-Principal Investigator
Total Direct Costs:	\$ 60,673
Total Amount of Award:	\$ 75,841
PI:	Craig, BM
Dates:	08/01/2008-12/31/2008
Source:	Merck
Title:	Evidence Synthesis for Modeling the Natural History of HPV-related Anal, Penile and Oropharyngeal Cancers.
% Effort:	25%
Role in the Study:	Principal Investigator
Total Direct Costs:	\$ 60,198
Total Amount of Award:	\$ 99,928
PI:	Skrepnek, G
Dates:	10/31/2004-09/30/2005
Source:	Eli Lilly
Title:	An Analysis of the Clinical and Economic Consequences of Disease Management Programs for the Treatment of Schizophrenia and Diabetes
% Effort:	5%
Role in the Study:	Co-Investigator
	Contributions include the proposal and design of a cost-effectiveness and secondary data analysis study.
Total Direct Costs:	\$ 125,044
Total Amount of Award:	\$ 125,044

Educational Grants:

Grant Account:	R25-CA147832
PI:	Egan, KM
Dates:	07/01/2010-6/30/2015
Source:	NCI
Title:	Moffitt Postdoctoral Training Program in Molecular & Genetic Epidemiology
% Effort:	0%
Role in the Study:	Program Faculty
Total Direct Costs:	\$ 1,865,926
Total Amount of Award:	\$ 2,015,200
Grant Account:	1D43TW008325
PI:	Giuliano, AR
Dates:	08/08/2009-07/31/2010
Source:	Fogarty International Center
Title:	Cancer Research Training in Morocco
Role in the Study:	Program Faculty
Total Amount of Award:	\$ 27,000
PI:	Craig, BM

Dates: 08/01/2005
Source: CVS Pharmacy
Title: Sponsorship of Educational Materials
Role in the Study: **Coordinator**
Total Amount of Award: \$ 279

PI: **Craig, BM**
Dates: 11/01/2004
Source: Caremark PCS
Title: Sponsorship of Educational Materials
Role in the Study: **Coordinator**
Total Amount of Award: \$ 6,222

Consultant:

Grant Account: NIHR127844
PI: Knight, M
Dates: 01/10/2020-30/09/2025
Source: UK NIHR
Title: Improving unwarranted variation in outcomes of children's surgery through a new Children's Surgery Outcome Reporting system using routinely available data (CSOR)
% Effort: 0%
Role in the Study: **Consultant**
Contributions include the proposal, design, conduct and publication of a stated-preference study.
Total Direct Costs: Not Applicable
Total Amount of Award: £ 2,177,431

Grant Account: 200-2008-27958, TO 26
PI: **Trogon, JG**
Dates: 09/01/2011 - 08/31/2013
Source: CDC
Title: Economic Burden of Breast Cancer in Young Women Aged 15-44 Years in the United States, 2000-2010
% Effort: 0%
Role in the Study: **Consultant**
Contributions include the proposal, design, conduct and publication of an outcomes study.
Total Direct Costs: \$245,199
Total Amount of Award: Unknown

Grant Account: 200-2008-F-26463
PI: **Brown, DS**
Dates: 07/22/2008 – 07/31/2012
Source: CDC
Title: Preference-Based Assessment of Child Maltreatment and Quality of Life
% Effort: 0%
Role in the Study: **Consultant**
Contributions include the design, conduct and publication of a discrete choice experiment.

Total Direct Costs: \$ 668,885
Total Amount of Award: Unknown

Dissertation

2003 *Doctoral Thesis:* Out-of-pocket Price, Prescription Medications, and Seniors. University of Wisconsin-Madison (Population Health), Madison, Wisconsin, USA.

Thesis Advisors: John Mullahy, Ph.D. (chair), Dennis Fryback, Ph.D., Barbara Wolfe, Ph.D., David Kindig, M.D. Ph.D., David H. Kreling, Ph.D., David A. Mott, Ph.D.

Service

Professional:

2013-Present **Editorial Board Member**, The Patient – Patient-Centered Outcomes Research.
2014-Present **Executive Director**, International Academy of Health Preference Research.
2017-Present **External Affiliate**, Erasmus Choice Modelling Centre.
2019-Present **Editorial Board Member**, Applied Health Economics and Health Policy.
2022-Present **Founder and Co-Editor**, R4HPR.org.
2022-Present **Member and Reviewer**, PhRMA Foundation Health Outcomes Research.
2022-2024 **Co-chair**, EuroQol PhD Network.
2014-2021 **Board Member**, International Academy of Health Preference Research.
2016-2021 **Co-Editor**, Value & Outcomes Spotlight (formerly known as Connections), International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
2018-2020 **Senior Regional Advisor**, Axentiva Solutions.
2014-2019 **Founder and Chair**, International Academy of Health Preference Research.
2014-2019 **Co-Founder and Co-Editor**, EuroQol Working Papers Series (EQ WPS), EuroQol Research Foundation.
2013-2017 **Freelancer**, EuroQol Research Foundation.
2014-2017 **Co-Founder and Co-Chair**, Health Preference Research Special Interest Group, International Society for Quality of Life Research (ISOQOL).
2005-2016 **Editorial Board Member**, Value & Outcomes Spotlight (formerly known as Connections), International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
2015 **Reviewer**, National Cancer Institute (NCI), Special Emphasis Panel, April 30, Bethesda, Maryland, USA.
2014 **Reviewer**, Agency for Healthcare Research and Quality (AHRQ), Special Emphasis Panel, November 13-14, Gaithersburg, Maryland, USA.
2014 **Reviewer**, Agency for Healthcare Research and Quality (AHRQ), Special Emphasis Panel, May 15-16, Gaithersburg, Maryland, USA.
2013-2014 **Member**, Conjoint Analysis Special Interest Group, International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
2011-2012 **Chair**, Health Outcomes Metrics Educational Working Group, International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
2011-2012 **Member**, Organizing Committee, Fourth Conjoint Analysis in Healthcare conference.
2005-2010 **Member**, Scientific Committee, American Society of Health Economist (ASHE).
2007, 2011 **Member**, Scientific Committee, International Health Economics Association (iHEA).
2009-2011 **Chair**, Health Econometrics Working Group, International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
2009-2011 **Executive Director**, International HPV Modeling Group (IHMG).
2009 **Reviewer**, Challenge Grants, Center for Scientific Review, DHHS/NIH.

2009	Chair , Modeling Evidence in HPV, Preconference Meeting, 25th Conference, International Papillomavirus Society (IPVS).
2008-2009	Co-Chair of the Workshop Review Committee, 14 th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
2008	Moderator , Podium Session II: Research on Medicare Part D and Reimbursement Policies II, International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
2007-2008	Member , ePRO Reviewer Group, International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
2005-2006	Chair , Contributed Poster Awards Task Force – Annual Meeting, Awards Committee, International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
2005-2006	Chair , Survey Subcommittee, Communications Task Force, International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
2005-2006	Member , Contributed Papers Awards Task Force – Annual Meeting, Awards Committee, International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
2005-2006	Member , Economic Outcomes Reference Group, Using "Real World" Data in Coverage and Reimbursement Decisions Task Force, International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
2005-2006	Member , Evidence Hierarchies Reference Group, Using "Real World" Data in Coverage and Reimbursement Decisions Task Force, International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

Professional Association Memberships

2001-Present	Member , International Health Economics Association (iHEA)
2003-Present	Member , International Society of Pharmacoeconomics & Outcomes Research (ISPOR)
2006-Present	Member , American Society of Health Economist (ASHE)
2008-Present	Member , EuroQol Group (EQ)
2014-Present	Member , International Academy of Health Preference Research (IAHPR)
2013-2020	Member , International Society for Quality of Life Research (ISOQOL)

Journal Reviewer*

Health Economics	The Patient
Value in Health	PharmacoEconomics
Applied Health Economics and Health Policy	Health and Quality of Life Outcomes
Social Science & Medicine	Economic Letters
Quality of Life Research	

** This list is limited to reviews completed over the last twelve months.*

Peer-Reviewed Publications

Papers in PubMed:

1. Jumamyradov M, **Craig BM**. Measuring Effectiveness Based on Patient Experience (Instead of QALYs) in US Value Assessments. *Pharmacoeconomics*. 2024 Nov 2;. doi: 10.1007/s40273-024-01444-1. [Epub ahead of print] PubMed PMID: 39487899.
2. **Craig BM**, Jumamyradov M, Rivero-Arias O. The Performance of Kaizen Tasks Across Three Online Discrete Choice Experiment Surveys: An Evidence Synthesis. *Patient*. 2024 Nov;17(6):635-644. doi: 10.1007/s40271-024-00708-4. Epub 2024 Jul 20. PubMed PMID: 39031285; PubMed Central PMCID: PMC11461645.

3. Jumamyradov M, **Craig BM**, Jakubczyk M. Scale and rate heterogeneity in the EQ-5D-5L valuation. *Health Qual Life Outcomes*. 2024 Jul 13;22(1):55. doi: 10.1186/s12955-024-02271-w. PubMed PMID: 39003479; PubMed Central PMCID: PMC11555889.
4. van Til JA, Pearce A, Ozdemir S, Hollin IL, Peay HL, Wu AW, Ostermann J, Deal K, **Craig BM**. Role Preferences in Medical Decision Making: Relevance and Implications for Health Preference Research. *Patient*. 2024 Jan;17(1):3-12. doi: 10.1007/s40271-023-00649-4. Epub 2023 Oct 24. PubMed PMID: 37874464; PubMed Central PMCID: PMC10769916.
5. Jumamyradov M, **Craig BM**, Rivero-Arias O, Jakubczyk M. Child health valuation protocol for a discrete choice experiment comparing paired comparison and kaizen tasks and estimating US EQ-5D-Y-3L values on an experience scale. *BMJ Open*. 2023 Oct 24;13(10):e077256. doi: 10.1136/bmjopen-2023-077256. PubMed PMID: 37879694; PubMed Central PMCID: PMC10603523.
6. Karim S, **Craig BM**, Tejada RA, Augustovski F. Preference heterogeneity in health valuation: a latent class analysis of the Peru EQ-5D-5L values. *Health Qual Life Outcomes*. 2023 Jan 2;21(1):1. doi: 10.1186/s12955-022-02079-6. PMID: 36593473; PMCID: PMC9808950.
7. Karim S, **Craig BM**, Vass C, Groothuis-Oudshoorn CGM. Current Practices for Accounting for Preference Heterogeneity in Health-Related Discrete Choice Experiments: A Systematic Review. *Pharmacoeconomics*. 2022 Oct;40(10):943-956. doi: 10.1007/s40273-022-01178-y. Epub 2022 Aug 12. PMID: 35960434.
8. Karim S, **Craig BM**, Groothuis-Oudshoorn CGM. Exploring the importance of controlling heteroskedasticity and heterogeneity in health valuation: a case study on Dutch EQ-5D-5L. *Health Qual Life Outcomes*. 2022 May 25;20(1):85. doi: 10.1186/s12955-022-01989-9. PMID: 35614472; PMCID: PMC9131619.
9. Rivero-Arias O, Buckell J, Allin B, **Craig BM**, Ayman G, Knight M; CSOR Collaborative Group. Using stated-preferences methods to develop a summary metric to determine successful treatment of children with a surgical condition: a study protocol. *BMJ Open*. 2022 Jun 9;12(6):e062833. doi: 10.1136/bmjopen-2022-062833. PMID: 35680263; PMCID: PMC9185585.
10. Vass C, Boeri M, Karim S, Marshall D, **Craig BM**, Ho KA, Mott D, Ngorsuraches S, Badawy SM, Mühlbacher A, Gonzalez JM, Heidenreich S. Accounting for Preference Heterogeneity in Discrete-Choice Experiments: An ISPOR Special Interest Group Report. *Value Health*. 2022 May;25(5):685-694. doi: 10.1016/j.jval.2022.01.012. PMID: 35500943.
11. **Craig BM**, de Bekker-Grob EW, González Sepúlveda JM, Greene WH. A Guide to Observable Differences in Stated Preference Evidence. *Patient*. 2021 Oct 26;1-11. doi: 10.1007/s40271-021-00551-x. Online ahead of print. PMID: 34697755
12. **Craig BM**, Rand K, Hartman JD. Preference Paths and Their Kaizen Tasks for Small Samples. *Patient*. 2021 Jul 30;1-10. doi: 10.1007/s40271-021-00541-z. Epub ahead of print. PMID: 34327605
13. **Craig BM**. United States COVID-19 Vaccination Preferences (CVP): 2020 Hindsight. *Patient*. 2021 May;14(3):309-318. doi: 10.1007/s40271-021-00508-0. Epub 2021 Mar 30. PMID: 33783724
14. Poteet S, **Craig BM**. QALYs for COVID-19: A Comparison of US EQ-5D-5L Value Sets. *Patient*. 2021 May;14(3):339-345. doi: 10.1007/s40271-021-00509-z. Epub 2021 Mar 30. PMID: 33782840
15. Karim S, **Craig BM**, Poteet S. Does Controlling for Scale Heterogeneity Better Explain Respondents' Preference Segmentation in Discrete Choice Experiments? A Case Study of US Health Insurance Demand. *Med Decis Making*. 2021 Jul;41(5):573-583. doi: 10.1177/0272989X21997345. Epub 2021 Mar 11. PMID:33703964.
16. Augustovski F, Belizán M, Gibbons L, Reyes N, Stolk E, **Craig BM**, Tejada RA. Peruvian Valuation of the EQ-5D-5L: A Direct Comparison of Time Trade-Off and Discrete Choice Experiments. *Value Health*. 2020 Jul;23(7):880-888. doi: 10.1016/j.jval.2020.05.004. Epub 2020 Jul 18. PMID: 32762989
17. Hollin IL, **Craig BM**, Coast J, Beusterien K, Vass C, DiSantostefano R, Peay H. Reporting Formative Qualitative Research to Support the Development of Quantitative Preference Study Protocols and Corresponding Survey Instruments: Guidelines for Authors and Reviewers. *Patient*. 2020 Feb;13(1):121-136. doi: 10.1007/s40271-019-00401-x. PMID: 31840215

18. Poteet S, **Craig BM**. The Value Employees Place on Health Insurance Plans: A Discrete-Choice Experiment. *Appl Health Econ Health Policy*. 2019 Dec;17(6):817-825. doi: 10.1007/s40258-019-00507-1 PMID: 31423545
19. Hartman JD, **Craig BM**. Does Device or Connection Type Affect Health Preferences in Online Surveys? *Patient*. 2019 Dec;12(6):639-650. doi: 10.1007/s40271-019-00380-z. PMID: 31364022
20. Norman R, **Craig BM**, Hansen P, Jonker MF, Rose J, Street DJ, Mulhern B. Issues in the Design of Discrete Choice Experiments. *Patient*. 2019 Jun;12(3):281-285. doi: 10.1007/s40271-018-0346-0. PMID: 30446958
21. **Craig BM**, Rand K, Bailey H, Stalmeier PFM. Quality-Adjusted Life-Years without Constant Proportionality. *Value Health*. 2018 Sep;21(9):1124-1131. doi: 10.1016/j.jval.2018.02.004. Epub 2018 Mar 27. PMID: 30224118
22. Hartman JD, **Craig BM**. Examining the Association Between Maternal Smoking During Pregnancy and Child Behavior Problems Using Quality-Adjusted Life Years. *Matern Child Health J*. 2018 Dec;22(12):1780-1788. doi: 10.1007/s10995-018-2577-z. PMID: 29995297
23. Ramos-Goñi JM, **Craig BM**, Oppe M, Ramallo-Fariña Y, Pinto-Prades JL, Luo N, Rivero-Arias O. Handling Data Quality Issues to Estimate the Spanish EQ-5D-5L Value Set Using a Hybrid Interval Regression Approach. *Value Health*. 2018 May;21(5):596-604. doi: 10.1016/j.jval.2017.10.023. Epub 2017 Dec 2. PMID: 29753358
24. **Craig BM**, Rand K. Choice Defines QALYs: A US Valuation of the EQ-5D-5L. *Med Care*. 2018 Jun;56(6):529-536. doi: 10.1097/MLR.0000000000000912. PMID: 29668646
25. Jakubczyk M, **Craig BM**, Barra M, Groothuis-Oudshoorn CGM, Hartman JD, Huynh E, Ramos-Goñi JM, Stolk EA, Rand K. Choice Defines Value: A Predictive Modeling Competition in Health Preference Research. *Value Health*. 2018 Feb;21(2):229-238. doi: 10.1016/j.jval.2017.09.016. Epub 2017 Nov 8. PMID: 29477405
26. Hartman JD, **Craig BM**. Comparing and transforming PROMIS utility values to the EQ-5D. *Qual Life Res*. 2018 Mar;27(3):725-733. doi: 10.1007/s11136-017-1769-0. Epub 2017 Dec 20. PMID: 29264776
27. **Craig BM**, Lancsar E, Mühlbacher AC, Brown DS, Ostermann J. Health Preference Research: An Overview. *Patient*. 2017 Aug;10(4):507-510. doi: 10.1007/s40271-017-0253-9. PMID: 28597377
28. Stolk EA, **Craig BM**, Mulhern B, Brown DS. Health Valuation: Demonstrating the Value of Health and Lifespan. *Patient*. 2017 Aug;10(4):515-517. doi: 10.1007/s40271-017-0252-x. PMID: 28597376
29. **Craig BM**, Monteiro AL, Herdman M, Santos M. Further evidence on EQ-5D-5L preference inversion: a Brazil/U.S. collaboration. *Qual Life Res*. 2017 May 8. doi: 10.1007/s11136-017-1591-8. PMID: 28484914
30. **Craig BM**, Mitchell SA. Examining the Value of Menopausal Symptom Relief among US Women. *Value Health* 2016 Mar;19(2):158-66. doi: 10.1016/j.jval.2015.11.002. Epub 2015 Dec 4. PMID: 27021749
31. Komrokji RS, Kulasekararaj A, Al Ali NH, Kordasti S, Bart-Smith E, **Craig BM**, Padron E, Zhang L, Lancet JE, Pinilla-Ibarz J, List AF, Mufti GJ, Epling-Burnette PK. Autoimmune diseases and myelodysplastic syndromes. *Am J Hematol*. 2016 May;91(5):E280-3. doi: 10.1002/ajh.24333. Epub 2016 Apr 4. PMID: 26875020
32. Brandon TH, Simmons VN, Sutton SK, Unrod M, Harrell PT, Meade CD, **Craig BM**, Lee JH, Meltzer LR. Extended Self-Help for Smoking Cessation: A Randomized Controlled Trial. *Am J Prev Med*. 2016 Feb 8. pii: S0749-3797(16)00011-8. doi: 10.1016/j.amepre.2015.12.01 PMID: 26868284
33. **Craig BM**, Hartman JD, Owens MA, Brown DS. Prevalence and Losses in Quality-Adjusted Life Years of Child Health Conditions: A Burden of Disease Analysis. *Matern Child Health J*. 2016 Apr;20(4):862-9. doi: 10.1007/s10995-015-1874-z. PMID: 26645618
34. Runge SK, **Craig BM**, Jim H. Word Recall: Cognitive Performance within Internet Surveys. *JMIR Ment Health*. 2015 Jun 2;2(2):e20. doi: 10.2196/mental.3969. eCollection 2015 Apr-Jun. PMID: 26543924
35. Lengacher CA, Kip KE, Reich RR, **Craig BM**, Mogos M, Ramesar S, Paterson CL, Farias JR, Pracht E. A Cost-Effective Mindfulness Stress Reduction Program: A Randomized Control Trial for Breast Cancer Survivors. *Nurs Econ*. 2015 Jul-Aug;33(4):210-8, 232. PMID: 26477119.

36. **Craig BM**. Unchained melody: revisiting the estimation of SF-6D values. *Eur J Health Econ*. 2016 Sep;17(7):865-73. doi: 10.1007/s10198-015-0727-4. Epub 2015 Sep 10. PMID: 26359242
37. **Craig BM**, Brown DS, Reeve BB. Valuation of Child Behavioral Problems from the Perspective of US Adults. *Medical Decision Making*. 2015 Jul 24. PMID: 26209476.
38. **Craig BM**, Brown DS, Reeve BB. The Value Adults Place on Child Health and Functional Status. *Value Health*. 2015 Jun;18(4):449-56. doi: 10.1016/j.jval.2015.02.012. Epub 2015 Apr 15. PMID: 26091599. PMCID: PMC4475576.
39. **Craig BM**, Greiner W, Brown DS, Reeve BB. Valuation of Child Health-Related Quality of Life in the United States. *Health Econ*. 2016 Jun;25(6):768-77. doi: 10.1002/hec.3184. Epub 2015 Apr 28. PMID: 25926161.
40. Unrod M, Simmons VN, Sutton SK, Meltzer LR, Harrell PT, Meade CD, **Craig BM**, Lee JH, Brandon TH. Relapse-Prevention Booklets as an Adjunct to a Tobacco Quitline: A Randomized Controlled Effectiveness Trial. *Nicotine & Tobacco Research*. 2015 Apr 6. pii: ntv079. [Epub ahead of print]. PMID: 25847293.
41. **Craig BM**, Runge SK, Rand-Hendriksen K, Ramos-Goñi JM, Oppe M. Learning and satisficing: An analysis of sequence effects in health valuation. *Value Health*. 2015 Mar;18(2):217-23. doi: 10.1016/j.jval.2014.11.005. Epub 2015 Feb 2. PMID: 2577357. PMCID: PMC4361790.
42. Owens MA, **Craig BM**, Egan KM, Reed DR. Birth desires and intentions of women diagnosed with a meningioma. *J Neurosurg*. 2015 May;122(5):1151-6. doi: 10.3171/2014.11.JNS14522. Epub 2015 Jan 27. PMID: 25623387.
43. **Craig BM**, Pickard AS, Rand-Hendriksen K. Do health preferences contradict ordering of EQ-5D labels? *Qual Life Res*. 2014. Dec; 18. PMID: 25519940 [Epub ahead of print].
44. **Craig BM**, Reeve BB, Brown PM, Cella D, Hays RD, Lipscomb J, Pickard S, Revicki DA. US valuation of health outcomes measured using the PROMIS-29. *Value Health*. 2014. Dec;17(8):846-53. PMID: 25498780. PMCID: PMC4471856.
45. Unrod M, Simmons VN, Sutton SK, Meltzer LR, Harrell PT, Meade CD, **Craig BM**, Lee JH, Brandon TH. A randomized clinical trial of self-help intervention for smoking cessation: Research design, interventions, and baseline data. *Contemporary Clinical Trials*. 2014 July; 38(2), 284-290. PMID: 24865525. PMCID: PMC4104245.
46. **Craig BM**, Donovan KA, Fraenkel L, Watson V, Hawley S, Quinn GP. A generation of childless women: lessons from the United States. *Women's Health Issues*. 2014 Jan-Feb;24(1):e21-7. PMID: 24439943.
47. **Craig BM**, Reeve BB, Cella D, Hays RD, Pickard AS, Revicki DA. Demographic Differences in Health Preferences in the United States. *Med Care*. 2014 Apr; PMID: 24374420. PMCID: PMC4031273.
48. **Craig BM**, Hays RD, Pickard AS, Cella D, Revicki DA, Reeve BB. Comparison of US Panel Vendors for Online Surveys. *J Med Internet Res*. 2013 Nov 29;15(11):e260. PMID: 2429215. PMCID: PMC3869804.
49. **Craig BM**, Pickard AS, Lubetkin EI. Health problems are more common, but less severe when measured using newer EQ-5D versions. *J Clin Epidemiol*. 2014 Jan;67(1):93-9. PMID: 24075597. PMCID: PMC4091801.
50. Kessler LM, **Craig BM**, Reed DR, Quinn GP, Plosker S. Infertility Evaluation and Treatment among Women in the United States. *Fertil Steril*. 2013 Oct;100(4):1025-32. PMID: 23849845. PMCID: PMC3814221.
51. **Craig BM**, Pickard AS, Stolk E, Brazier JE. US Valuation of the SF-6D. *Med Decis Making*. 2013 Aug;33(6):793-803. PMID: 23629865. PMCID: PMC3740344.
52. **Craig BM**, Han G, Munkin MK, Fenstermacher D. Simulating the contribution of a biospecimen and clinical data repository in a phase II clinical trial: a value of information analysis. *Stat Methods Med Res*. 2013 Mar 15. [Epub ahead of print]. PMID: 23503303. PMCID: PMC3752320.
53. Kessler LM, **Craig BM**, Saigal C, Quinn GP. Starting a Family: Characteristics Associated With Men's Reproductive Preferences. *Am J Mens Health*. 2013 May;7(3):198-205. Epub 2012 Oct 29. PMID: 23112251. PMCID: PMC3708672.

54. Tarn DM, Young HN, **Craig BM**. Development of the patient approach and views toward healthcare communication (PAV-COM) measure among older adults. *BMC Health Serv Res*. 2012 Aug 30; 12:289. PMID: 22931537. PMCID: PMC3496598.
55. Pidala J, **Craig BM**, Lee S, Majhail N, Quinn GP, Anasetti C. Practice variation in physician referral for allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant*. 2013 Jan;48(1):63-7. PMID: 227905801. PMCID: PMC3549547.
56. **Craig BM**, Rollison DE, List AF, Cogle CR. Underreporting of myeloid malignancies by United States cancer registries. *Cancer Epidemiol Biomarkers Prev*. 2012 Mar;21(3):474-81. PMID: 22237987. PMCID: PMC3662977.
57. Adams R, **Craig BM**, Veale D, Bresnihan B, Walsh C, FitzGerald O, Barry M. The Impact of a Revised EQ-5D Population Scoring on Preference-based Utility Scores in an Inflammatory Arthritis cohort. *Value Health*. 2011 Sep-Oct;14(6):921-7. PMID: 21914514. PMCID: PMC3811927.
58. **Craig BM**, Rollison DE, List AF, Cogle CR. Diagnostic Testing, Treatment, Cost of Care, and Survival among Registered and Non-registered Patients with Myelodysplastic Syndromes. *Leuk Res*. 2011 Nov; 35(11):1453-6. PMID: 21851978. PMCID: PMC3191243.
59. Rowen D, Brazier J, Young T, Gaugris S, King MT, **Craig BM**, Velikova G. Deriving a Preference-Based Measure for Cancer using the EORTC QLQ-C30. *Value Health*. 2011 Jul-Aug;14(5):721-31. PMID: 21839411. PMCID: PMC3811066.
60. **Craig BM**, Busschbach JJV. Revisiting United States Valuation of EQ-5D States. *J Health Econ*. 2011 Sep 30; (5):1057-63. PMID: 21835477. PMCID: PMC3188390.
61. Cogle CR, **Craig BM**, Rollison DE, List AF. Incidence of the Myelodysplastic Syndromes using a Novel Claims-Based Algorithm: High Number of Uncaptured Cases by Cancer Registries. *Blood*. 2011 Jun 30;117(26):7121-5. PMID: 21531980. PMCID: PMC3143554.
62. **Craig BM**, Brisson M, Chesson H, Giuliano AR, Jit M. Proceedings of the Modeling Evidence in HPV Pre-Conference Workshop in Malmö, Sweden, May 9-10, 2009. *Clin Ther*. 2010 Aug;32(8):1546-64. PMID: 20728767. PMCID: 4095755.
63. **Craig BM**, Busschbach JJV. Toward a more universal approach in health valuation. *Health Econ*. 2011 Jul; 20(7):864-75. PMID: 20677328. PMCID: PMC3819815.
64. **Craig BM**, Gilbert SM, Herndon JB, Vogel B, Quinn GP. Participation of older patients with prostate cancer in Medicare eligible trials. *J Urol*. 2010 Sep;184(3):901-6. PMID: 20643449. PMCID: PMC3811922.
65. **Craig BM**, Bell BA, Quinn GP, Vadaparampil ST. Prevalence of Cancer Visits by Physician Specialty, 1997-2006. *J Cancer Educ*. 2010 Dec;25(4):548-55. PMID: 20336400. PMCID: PMC3811914.
66. **Craig BM**, Strassels S. Out-of-Pocket Prices of Opioid Analgesics in the United States, 1999-2004. *Pain Med*. 2010 Feb;11(2):240-7. PMID: 20002589. PMCID: PMC3811926.
67. Augustovski FA, Irazola VE, Velazquez AP, Gibbons L, **Craig BM**. Argentine Valuation of the EQ-5D Health States. *Value Health*. 2009 Jun;12(4):587-96. PMID: 19090257. PMCID: PMC3819816.
68. **Craig BM**, Oppe M. From a different angle: a novel approach to health valuation. *Soc Sci Med*. 2010 Jan;70(2):169-74. PMID: 19880235. PMCID: PMC2808428.
69. **Craig BM**, Quinn G, Vadaparampil S. Sensitivity of self-report mammography use in older women. *Am J Prev Med*. 2009 Nov;37(5):441-4. PMID: 19840700. PMCID: PMC3864094.
70. Rakel DP, Hoeft TJ, Barrett BP, Chewning BA, **Craig BM**, Niu M. Practitioner Empathy and the Duration of the Common Cold. *Fam Med*. 2009 Jul-Aug;41(7):494-501. PMID: 19582635. PMCID: PMC2720820.
71. **Craig BM**, Busschbach JJV, Salomon J. Modeling Ranking, Time Trade-Off and Visual Analogue Scale Values for EQ-5D Health States: A Review and Comparison of Methods. *Med Care*. 2009 Jun;47(6):634-41. PMID: 19433996. PMCID: PMC2730922.
72. **Craig BM**, Busschbach JJV. The Episodic Random Utility Model Unifies Worse Than Death and Better Than Death TTO Responses in Health State Valuation. *Popul Health Metr*. 2009 Jan 13;7:3. PMID: 19144115. PMCID: PMC2667164.

73. **Craig BM**, Busschbach JJV, Salomon J. Keep It Simple: Ranking Health States Yields Values Similar to Cardinal Measurement Approaches. *J Clin Epidemiol*. 2009 Mar;62(3):296-305. PMID: 18945585. PMCID: PMC2766172.
74. **Craig BM**, Kraus C, Davis J, Chewning B. Quality of care for older adults with chronic obstructive pulmonary disease and asthma based on comparisons to practice guidelines and smoking status. *BMC Health Serv Res*. 2008 Jul 8;8:144. PMID: 18611245. PMCID: PMC2500012.
75. **Craig BM**, Adams AK. Accuracy of Body Mass Index Categories Based on Self-reported Height and Weight among Women in the United States. *Matern Child Health J*. 2009 Jul;13(4):489-96. PMID: 18607705. PMCID: PMC2731685.
76. **Craig BM**. The duration effect: a link between TTO and VAS values. *Health Econ*. 2009 Feb;18(2):217-25. PMID: 18351621. PMCID: PMC2760230.
77. **Craig BM**, Ramachandran S. Relative Risk of a Shuffled Deck: A Generalizable Logical Consistency Criterion for Sample Selection in Health State Valuation Studies. *Health Econ*. 2006 Aug;15(8):835-48. PMID: 16532509.
78. Lundy JJ, **Craig BM**. The use of disease-modifying agents among multiple sclerosis patients enrolled in medicare from 1995 to 2002 and the impact of medicare part D: analysis of claims data from the medicare current beneficiary survey. *Clin Ther*. 2006 Jan;28(1):140-5. PMID: 16490588.
79. Herman P, **Craig BM**, Caspi O. Is Complementary and Alternative Medicine (CAM) Cost-Effective? A Systematic Review. *BMC Complement Altern Med*. 2005 Jun 2;5:11. PMID: 15932647. PMCID: PMC1182346.
80. Fryback D, **Craig BM**. Measuring economic outcomes of cancer. *J Natl Cancer Inst Monogr*. 2004;(33):134-41. PMID: 15504924.
81. **Craig BM**, Kreling DH, Mott DA. Do Seniors Get The Medicines Prescribed For Them? Evidence From the 1996-1999 Medicare Current Beneficiary Survey. *Health Aff (Millwood)*. 2003 May-Jun;22(3):175-82. PMID: 12757282.
82. **Craig BM**, Tseng DS. Cost-effectiveness of Gastric Bypass for Severe Obesity. *Am J Med*. 2002 Oct 15;113(6):491-8. PMID: 12427499.
83. **Craig BM**, Koc C. Vice-President Al Gore's Health Care Agenda and the Utilization of Medical Services: An Empirical Analysis. *MedGenMed*. 2000 Oct 27;2(4):E33. PMID: 11104479.

Other Peer-Reviewed Papers:

84. Jumamyradov M, **Craig BM**, Munkin M, and Greene WH. (2024). Comparing the Mixed Logit Estimates and True Parameters Under Informative and Uninformative Heterogeneity: A Simulated Discrete Choice Experiment. *Computational Economics*. doi.org/10.1007/s10614-024-10637-x
85. Jumamyradov M, Munkin M, Greene WH and **Craig BM**. (2024). Biases in the Maximum Simulated Likelihood Estimation of the Mixed Logit Model. *Econometrics*, 12(2), 8. doi.org/10.3390/econometrics12020008
86. Jumamyradov M, **Craig BM**, Munkin M, Greene WH. Comparing the Conditional Logit Estimates and True Parameters under Preference Heterogeneity: A Simulated Discrete Choice Experiment. *Econometrics*. 2023; 11(1):4. <https://doi.org/10.3390/econometrics11010004>
87. Craig, SC, **Craig, BM**. United States Public Perceptions of Middle Eastern or North African (MENA) as a Racial Category. *Analyses of Social Issues and Public Policy*. 19(1) 246-255. doi:10.1111/asap.12185

Book Chapters

1. **Craig BM**. Assessing the economic value of cancer prevention. In: *Fundamentals of Cancer Prevention*, fourth edition. DS Alberts & LM Hess (Eds). Springer-Verlag, 2019. https://doi.org/10.1007/978-3-030-15935-1_3.
2. Coons SJ, **Craig BM**. Assessing human and economic benefits of cancer prevention. In: *Fundamentals of Cancer Prevention*, third edition. DS Alberts & LM Hess (Eds). Springer-Verlag, 2014.

3. Coons SJ, **Craig BM**. Assessing human and economic benefits of cancer prevention. In: Fundamentals of Cancer Prevention, second edition. DS Alberts & LM Hess (Eds). Springer-Verlag, pp13-30, 2008.
4. Coons SJ, **Craig BM**. Assessing human and economic benefits of cancer prevention. In: Fundamentals of Cancer Prevention, first edition, DS Alberts & LM Hess (Eds.) Springer-Verlag, pp11-24, 2005.
5. Gould, E, **Craig BM**, Nahl M, et al. Health Insurance, National Approaches. In: Encyclopedia of Aging, New York: Macmillan Reference. D. J. Ekerts (Eds.) pp593-600, 2002.

Papers in Published Proceedings and Working Paper Series

1. Augustovski F, Belizán M, Gibbons L, Reyes N, Stolk EA, **Craig BM**, Tejada RA, EuroQol EQ-5D-5L Value Set in Peru using a “Lite” protocol. Proceedings of the 37th Scientific Plenary Meeting of the EuroQol Group, September 2020.
2. Hartman JD, **Craig BM**, Learning Curves and sequence effects. Proceedings of the 36th Scientific Plenary Meeting of the EuroQol Group, September 2019.
3. Stolk EA, Norman R, de Bekker-Grob E, **Craig BM**, Donkers B, Jonker M, Mulhern B, Viney R, Discrete choice models with duration: validity conditions. Proceedings of the 35th Scientific Plenary Meeting of the EuroQol Group, September 2018.
4. Pinto-Prades JL, Sanchez Martínez F, Ramos-Goñi JM, Rand K, **Craig BM**, the disparity between classic and chained utilities: implications for preference elicitation in health care. Proceedings of the 35th Scientific Plenary Meeting of the EuroQol Group, September 2018.
5. Hartman JD, **Craig BM**. Learning Curves and Sequence Effects. Proceedings of the 35th Scientific Plenary Meeting of the EuroQol Group, September 2018.
6. Hartman JD, **Craig BM**. Do Device and Location affect Health Preference Data Quality? Proceedings of the 34nd Scientific Plenary Meeting of the EuroQol Group, September 2017.
7. Ramos Goñi JM, **Craig BM**, Oppe M, van Hout B, Combining continuous and dichotomous responses in a hybrid model. EuroQol Working Paper Series, December 2016.
8. Santos M, Monteiro AL, **Craig BM**. Further evidence on EQ-5D-5L preference inversion: A Brazil/US Collaboration. Proceedings of the 32nd Scientific Plenary Meeting, EuroQol Group, September 2015.
9. Hartman JD, **Craig BM**, Comparison of PROMIS and EQ-5D Quality-Adjusted Life Years. Proceedings of the 32nd Scientific Plenary Meeting of the EuroQol Group, September 2015.
10. **Craig BM**, Ramos Goñi JM, Shaw JW, Flynn TN. Majority Rule: How to integrate TTO and DCE responses to increase construct validity and reduce parameter uncertainty. Proceedings of the 30th Scientific Plenary Meeting of the EuroQol Group, September 2013.
11. **Craig BM**, Brown DS, Cunningham C, Greiner W, Reeve BB. United States Valuation of Child Health Outcomes. Proceedings of the 30th Scientific Plenary Meeting of the EuroQol Group, September 2013.
12. **Craig BM**. From a different angle: a novel approach to health valuation. Proceedings of the 26th Scientific Plenary Meeting of the EuroQol Group, 121-135, September 2009.
13. **Craig BM**, Pickard S. Variability in QALY values for chronic conditions. Proceedings of the 26th Scientific Plenary Meeting of the EuroQol Group, 155-164, September 2009.
14. Augustovski FA, Irazola VE, Velazquez AP, Gibbons L, **Craig BM**. To develop a set of EQ-5D health state values for the Argentine general population. Proceedings of the 25th Scientific Plenary Meeting of the EuroQol Group, 133-148, September 2008.
15. **Craig BM**, Busschbach JJV. Replacing ad hoc adjustments for TTO values below death with a consistent theoretical model: increasing validity and power. Proceedings of the 25th Scientific Plenary Meeting of the EuroQol Group, 199-214, September 2008.
16. Gu NY, **Craig BM**, Doctor J. Diagnosing the EQ-5D items using the Rasch Models in a US Representative Sample. Proceedings of the 25th Scientific Plenary Meeting of the EuroQol Group, 309-330, September 2008.
17. **Craig BM**, Busschbach JJV, Salomon J. International Valuation Set for EQ-5D Health States. Proceedings of the 24th Scientific Plenary Meeting of the EuroQol Group, 301-318, September 2007.

18. **Craig BM**, Buschbach JJV, Salomon J. Ordinal valuation of health states: a seven country study. Proceedings of the 23rd Scientific Plenary Meeting of the EuroQol Group, 415-435, August 2006.

Other Research and Creative Works

1. **Craig BM**, González Sepúlveda JM, Johnson FR, Kessels R, Reed S, Sandorf E, Shah K, Tervonen T, Watson V, COVID-19 Health Preference Research: Four Lessons Learned, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Value and Outcomes Spotlight. Vol. 6(4), 2020.
2. **Craig BM**, Joshi N, Member Survey Report, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Health Preference Research Special Interest Group. 6 November 2018
3. Beusterien K, **Craig BM**, The Increasing Role of Qualitative Evidence on Health Preferences for Regulatory Decision Making, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Value and Outcomes Spotlight. Vol. 3(6), 2017.
4. **Craig BM**. What is the value of a health outcome? Quality of Life Quarterly: Newsletter for ISOQOL Members. September 2017.
5. **Craig BM**, Mühlbacher AC. Health Preference Study and Technology Registry (hpstr.org). March 2017.
6. Owens MA, **Craig BM**, Tuite G, Reed DR. Women's Risk of Meningioma Recurrence: The Experiences of a Survivor Support Group. AANS Neurosurgeon 24 (3). 2015
7. **Craig BM**, Mühlbacher AC. Choice Defines Value: An Invitation to Participate in the Health Preference Research Special Interest Group. Quality of Life Quarterly: Newsletter for ISOQOL Members. 2014:1-12.
8. **Craig BM**, Mühlbacher AC. Patient's Choices Define Value: Why we should listen to consumers and citizens. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Connections. Vol. 19(Compendium), 2013.
9. González JM, **Craig BM**, Mühlbacher AC. Choice Defines Value: Using Discrete-Choice Experiments to Understand and Inform Health Care Decisions. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Connections. Vol. 19(2), 2013.
10. **Craig BM**, Reeve BB. Patient-Reported Outcomes and Preference Research: Igniting the Candle at Both Ends and the Middle. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Connections. Vol. 18(5):24, 2012.
11. **Craig BM**. Thoughts on the Validity of a New QALY Estimator [Response]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Connections. Vol. 16(1):24, 2010.
12. **Craig BM**. Authorship in Economic Evaluations. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Connections. Vol. 14(1): 23-24, 2008.
13. **Craig BM**. Career Pathways in Pharmacoeconomics and Outcomes Research. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Connections. Vol. 13(5): 21, 2007.
14. **Craig BM**, Benish K, Lipscomb J. PRODUCE Results Today! The Motivation behind the Next National Cancer Act. Working Paper, Moffitt Cancer Center, Tampa, Florida. pp. 1-34. December 17, 2007.
15. Barham B, Coomes O, **Craig BM**. Uso de recursos por los ribereños en la Reserva Nacional Pacaya-Samiria: Datos de una encuesta reciente e implicaciones para el manejo del area protegida. Espacio y Desarrollo, 8: 5-32, 1996.
16. Coomes OT, Barham BL, **Craig BM**. Resource extraction and the forest peasant household: Results of analyses of IIAP data from the Pacaya-Samiria National Reserve. Working Paper, the Nature Conservancy, Arlington, VA. pp. 1-38, 1996.
17. Barham BL, Coomes OT, **Craig BM**, Tarasoff P. Wealth and the forest peasant household: Evidence from the Tahuayo and the Pacaya-Samiria National Reserve. Working Paper, the Nature Conservancy, Arlington, VA. pp. 1-26 1995.

Scientific Abstracts/Podium Presentations/Poster Presentations

1. **Craig BM**, Peasgood T, Pham M, Rencz F, A Direct Comparisons of the Measurement and Conceptual Properties of the EQ-5D-5L and PROMIS®-16 in a US General Population Sample, 41st EuroQol Plenary, Noordwijk, the Netherlands, 19 September 2024
2. Jumamyradov M, **Craig BM**, Jakubczyk, Rivero-Arias O, Valuation of Child Health-Related Quality of Life by Child Age and Problem Duration, 41st EuroQol Plenary, Noordwijk, the Netherlands, 19 September 2024
3. Jumamyradov M, **Craig BM**, Munkin M, Greene W, Comparing the Conditional Logit Estimates and True Values Under Preference Heterogeneity: A Simulated Discrete Choice Experiment in Health Valuation, 12th Annual Conference of the American Society of Health Economists, St. Louis, Missouri, USA, 13 June 2023
4. Jumamyradov M, **Craig BM**, Munkin M, Greene W, Comparing the Mixed Logit Estimates and True Values Under Informative and Uninformative Heterogeneity: A Simulated Discrete Choice Experiment in Health Valuation, 12th Annual Conference of the American Society of Health Economists, St. Louis, Missouri, USA, 13 June 2023
5. Jumamyradov M, **Craig BM**, Jakubczyk M, Scale and Rate heterogeneity in EQ-5D-5L Valuation, 12th Annual Conference of the American Society of Health Economists, St. Louis, Missouri, USA, 13 June 2023
6. Karim S, **Craig BM**, Augustovski F, Importance of Scale Adjustment in Preference Heterogeneity Analysis in Health Valuation: Application in Peru EQ-VT Data, EuroQol Topical Meeting, Online, August 2021.
7. Augustovski F, Belizán M, Gibbons L, Reyes N, Stolk EA, **Craig BM**, Tejada RA, Peruvian Valuation of the EQ-5D-5L: a direct comparison of TTO and DCE. International Academy of Health Preference Research, 11th Meeting, Auckland, New Zealand, December 2019.
8. Mühlbacher AC, **Craig BM**, Bekker-Grob E, Ramos-Goñi JM, Groothuis-Oudshoorn CGM, Choice defines value: decisions, steps, obstacles and outreach in health preference research, International Society for Pharmacoeconomics and Outcomes Research 21th Annual European Congress, Barcelona, Spain, October 2019.
9. Karim S, **Craig BM**, Poteet SP, LC vs. SALC: Choosing Between Latent Class Models of Preference Heterogeneity, 10th Meeting. Basel, Switzerland. July 2019.
10. Poteet SP, **Craig BM**, HPSTR report on quality-adjusted life year estimates in Alzheimer's disease. [poster] 10th Meeting. Basel, Switzerland. July 2019.
11. **Craig BM**, Hartman JD, Oppe M, From a different angle: a novel approach to modeling health preferences, International Academy of Health Preference Research. 9th Meeting. Montréal, Québec, Canada. October 2018.
12. Poteet S, **Craig BM**, The Value U.S. employees place on health insurance. International Academy of Health Preference Research. 8th Meeting. Hobart, Australia. September 2018.
13. Poteet S, **Craig BM**, Brown D. Lexicographic Preferences in U.S. Health Insurance Marketplace: the case of single employees. International Academy of Health Preference Research. 7th Meeting. Glasgow, UK. November 2017.
14. Stolk EA, Norman R, de Bekker-Grob E, **Craig BM**, Donkers B, Jonker M, Mulhern B, Viney R, Discrete choice models with duration: validity conditions. Proceedings of the 35th Scientific Plenary Meeting of the EuroQol Group, September 2018.
15. Pinto-Prades JL, Sanchez Martínez F, Ramos-Goñi JM, Rand K, **Craig BM**, the disparity between classic and chained utilities: implications for preference elicitation in health care. Proceedings of the 35th Scientific Plenary Meeting of the EuroQol Group, September 2018.
16. Hartman JD, **Craig BM**. Learning Curves and Sequence Effects. Proceedings of the 35th Scientific Plenary Meeting of the EuroQol Group, September 2018.

17. Craig BM, Rand K. Choice Defines QALYs: A US Valuation of the EQ-5D-5L. International Society for Pharmacoeconomics and Outcomes Research, 23rd Annual Meeting, Baltimore, Maryland, USA, May 2018.
18. Poteet S, **Craig BM**, US EQ-5D-5L Values by Self-reported Health. [poster]. EuroQol Group. 3rd EuroQol Academy Meeting. Budapest, Hungary. March 2018.
19. **Craig BM**. Lexicographic preferences in lifespan: an inconvenient truth. International Academy of Health Preference Research. 7th Meeting. Glasgow, UK. November 2017.
20. Poteet S, **Craig BM**, Brown D. Lexicographic Preferences in U.S. Health Insurance Marketplace: the case of single employees. International Academy of Health Preference Research. 7th Meeting. Glasgow, UK. November 2017.
21. Hartman J, **Craig BM**. Learning Curves and Sequence Effects. International Academy of Health Preference Research. 7th Meeting. Glasgow, UK. November 2017.
22. **Craig BM**, Rand-Hendriksen K. US Valuation of the EQ-5D-5L. International Society for Quality of Life Research, 24th Annual Conference, Philadelphia, Pennsylvania, USA. October 2017.
23. **Craig BM**, Rand-Hendriksen K. US Valuation of the EQ-5D-5L [poster]. EuroQol Group. 34th EuroQol Plenary Meeting. Barcelona, Spain. September 2017.
24. Hartman J, **Craig BM**. Does Device or Connection affect Health Preferences using Online Surveys?, EuroQol Group. 34th EuroQol Plenary Meeting. Barcelona, Spain. September 2017.
25. **Craig BM**, Rand-Hendriksen K. US Valuation of the EQ-5D-5L. International Academy of Health Preference Research, 6th Meeting, Boston, USA. July 2017
26. Hartman J, **Craig BM**. Time of Day and EQ-5D-5L Responses [poster], EuroQol Group. 2nd EuroQol Academy Meeting. Noordwijk aan Zee, the Netherlands. March 2017.
27. Hartman J, **Craig BM**. Logical Inconsistencies in EQ-5D-5L Discrete Choice Experiments [poster], EuroQol Group. 2nd EuroQol Academy Meeting. Noordwijk aan Zee, the Netherlands. March 2017.
28. **Craig BM**. Drop Dead: an empirical evaluation of the “immediate death” alternative in DCE [poster], EuroQol Group. 2nd EuroQol Academy Meeting. Noordwijk aan Zee, the Netherlands. March 2017.
29. Hartman J, **Craig BM**. Comparison of Parent and Non-parent Preferences in Valuation of Child Health [poster], EuroQol Group. 33rd Plenary Meeting. Berlin, Germany. September 2016.
30. **Craig BM**, Rand-Hendriksen K. DCE Predictive Modeling Competition: A Review of Exploratory Evidence and Team Predictions, International Academy of Health Preference Research. 5th Meeting. Singapore. September 2, 2016 13:30-15:00
31. Oppe M, **Craig BM**. Variability in DCE results due to sample size and design size, International Academy of Health Preference Research. 5th Meeting. Singapore. September 2, 2016 13:30-15:00
32. **Craig BM**, Rand-Hendriksen K, Bailey H, Stalmeier PFM. Quality-adjusted Life Years without Constant Proportionality, International Academy of Health Preference Research. 4th Meeting. Hamburg, Germany. July 13, 2016 11:15AM-12:15PM.
33. Hartman J, **Craig BM**. Comparison of PROMIS and EQ-5D Quality-adjusted Life Years. International Society for Quality of Life Research, 22nd Annual Conference, Vancouver, British Columbia, Canada. October 23, 2015 4:05-5:35PM.
34. **Craig BM**, Montiero AL, Santos M. Further Evidence on EQ-5D-5L Preference Inversion: A Brazil/US Collaboration [poster], International Society for Quality of Life Research, 22nd Annual Conference, Vancouver, British Columbia, Canada. October 24, 2015 10:25-10:45AM.
35. Runge SK, **Craig BM**. Respondent Cognition in Health Preference Research, International Academy of Health Preference Research. 3rd Meeting. St. Louis, Missouri, USA. October 18 2015.
36. Hartman J, **Craig BM**. Comparison of PROMIS and EQ-5D Quality-adjusted Life Years [poster], International Academy of Health Preference Research. 3rd Meeting. St.Louis, Missouri, USA. October 18 2015.
37. Owens MA, **Craig BM**. The Valuation of the EQ-5D from the Perspective of US Patients with Cancer. 2nd Meeting. Brisbane, Queensland, Australia. September 29, 2015.

38. **Craig BM**, Mitchell SA. Examining the Value of Menopausal Symptom Relief among US Women, International Academy of Health Preference Research. 2nd Meeting. Brisbane, Queensland, Australia. September 29, 2015.
39. Santos M, Monteiro AL, **Craig BM**. Further evidence on EQ-5D-5L preference inversion: A Brazil/US Collaboration, EuroQol Group. 32st Plenary Meeting. Krakow, Poland. September 2015.
40. **Craig BM**. Does changing the order of the EQ-5D questions change their responses? [poster], EuroQol Group. 32st Plenary Meeting. Krakow, Poland. September 2015.
41. Hartman J, **Craig BM**. Comparison of PROMIS and EQ-5D Quality-adjusted Life Years [poster], EuroQol Group. 32st Plenary Meeting. Krakow, Poland. September 2015.
42. **Craig BM**, Brown DS, Reeve BB. The Value Adults Place on Child Health and Functional Status [poster], International Society for Pharmacoeconomics and Outcomes Research, 20th Annual Meeting, Philadelphia, Pennsylvania, USA, May 2015.
43. **Craig BM**, Greiner W, Brown DS, Reeve BB. Valuation of Child Health-related Quality of Life in the United States [poster], International Society for Pharmacoeconomics and Outcomes Research, 20th Annual Meeting, Philadelphia, Pennsylvania, USA, May 2015.
44. **Craig BM**, Mitchell SA. The Value Women Place on Menopausal Symptoms [poster], , International Society for Pharmacoeconomics and Outcomes Research, 20th Annual Meeting, Philadelphia, Pennsylvania, USA, May 2015.
45. Hartman J, **Craig BM**, Owens MA, Brown DS. Prevalence and Losses in Quality-Adjusted Life Years of Child Health Conditions: a Burden of Disease Analysis [poster], International Society for Pharmacoeconomics and Outcomes Research, 20th Annual Meeting, Philadelphia, Pennsylvania, USA, May 2015.
46. Runge SK, **Craig BM**, Reeve BB. Choosing between the PROMIS Global And EQ-5D for Comparative Effectiveness Research: Are They Really Different?, 20th Annual Meeting, Philadelphia, Pennsylvania, USA, May 2015.
47. Hartman J, **Craig BM**. Comparison of PROMIS and EQ-5D Quality-adjusted Life Years, PROMIS Health Organization, Inaugural Conference, Philadelphia, Pennsylvania, USA, May 2015.
48. Runge SK, **Craig BM**, Reeve BB. Choosing between the PROMIS Global And EQ-5D for Comparative Effectiveness Research: Are They Really Different?, PROMIS Health Organization, Inaugural Conference, Philadelphia, Pennsylvania, USA, May 2015.
49. **Craig BM**. Fifth Wheel: Evidence of Disagreements between Health Scales and Preferences in the EQ-5D [poster], International Society for Quality of Life Research, 21st Annual Conference, Berlin, Germany. October 2014.
50. **Craig BM**. Fifth Wheel: Evidence of Disagreements between Health Scales and Preferences in the EQ-5D, EuroQol Group. 31st Plenary Meeting. Stockholm, Sweden. September 2014.
51. **Craig BM**. United States Valuation of the EQ-5D-3L, EQ-5D-Y, and EQ-5D-5L [poster], EuroQol Group. 31st Plenary Meeting. Stockholm, Sweden. September 2014.
52. **Craig BM**, Reeve BB, Brown PM, Cella D, Hays RD, Lipscomb J, Pickard AS, Revicki DA. Valuation of Health Outcomes Measured Using the PROMIS-29, Conjoint Analysis in Healthcare, Dana Point, California, USA. October 2013.
53. **Craig BM**, Reeve BB, Brown PM, Cella D, Hays RD, Lipscomb J, Pickard AS, Revicki DA. Valuation of Health Outcomes Measured Using the PROMIS-29, International Society for Quality of Life Research, 20th Annual Conference, Miami, Florida, USA. October 2013.
54. **Craig BM**, Brown DS, Greiner W, Reeve BB. United States Valuation of Child Health Outcomes [Poster], International Society for Quality of Life Research, 20th Annual Conference, Miami, Florida, USA. October 2013.
55. **Craig BM**, Brown DS, Cunningham C, Greiner W, Reeve BB. United States Valuation of Child Health Outcomes, EuroQol Group. 30th Plenary Meeting. Montreal, Canada. September 2013.
56. **Craig BM**, Ramos Goñi JM, Shaw JW, Flynn TN. Majority Rule: How to Integrate TTO and DCE Responses to Increase Construct Validity and Reduce Parameter Uncertainty, EuroQol Group. 30th Plenary Meeting. Montreal, Canada. September 2013.

57. Ratcliffe J, Chen G, **Craig BM**, Stevens K, Brazier J, Huynh E, Sawyer M, Roberts R, Flynn TN. Assessing the health related quality of life of Australian adolescents: findings from application of the EQ-5D-Y in a community based on-line survey [poster], EuroQol Group. 30th Plenary Meeting. Montreal, Canada. September 2013.
58. **Craig BM**, Brown DS, Cunningham C, Greiner W, Reeve BB. United States Valuation of Child Health Outcomes [poster], International Society for Pharmacoeconomics and Outcomes Research, 15th Annual European Congress, Berlin, Germany, November 2012.
59. **Craig BM**, Watson V, Busschbach JJV. Choice-based valuation of the SF-12v1 [poster], International Society for Pharmacoeconomics and Outcomes Research, 15th Annual European Congress, Berlin, Germany, November 2012.
60. **Craig BM**, Watson V. Choice-based Valuation of the SF-12. The 4th Conjoint Analysis in Health Conference. Orlando, Florida, USA. March 2012.
61. Lengacher CA, Jim H, Reich R, Pracht E, **Craig BM**, Ramesar R, Carranza I, Paterson C, Budhrani P, Millette L, Hogue DL, Wooten K, Mogos M, Johnson Mallard V, Santiago S, Miglore M, Dameron M, Kip KE. Improving Quality of Life in Breast Cancer Survivors: The Cost-Effectiveness of Mindfulness Based Stress Reduction [poster]. 9th Annual Conference of the American Psychosocial Oncology Society. Miami, Florida, USA. February 2012.
62. **Craig BM**. Arctangent Model for Conjoint Analysis. American Health Econometrics Working Group. Ann Arbor, Michigan. October 2010.
63. Gu NY, Bond TG, **Craig BM**. Evaluating the Measurement Properties of an Augmented EQ-5D Using the US National Representative Sample. International Conference on Outcomes Measurement. Bethesda, Maryland, USA. September 2010.
64. Oppe M, **Craig BM**. From a different angle: The use of directional statistics in ICER calculations. 8th European Conference on Health Economics. Helsinki, Finland. July 2010.
65. Adams R, **Craig BM**, Walsh C, Veale D, Bresnihan B, Barry M, FitzGerald O. A revised scoring system for the EQ-5D produces a change in preference-based utility score, which is closer to disease measures in inflammatory arthritis. 8th HTAi 2010 Conference. Dublin, Ireland. June 2010.
66. **Craig BM**, Brazier J. Unchained Melody: Revisiting the estimation of SF-6D values. American Society of Health Economists (ASHE), Health, Healthcare & Behavior. 3rd Biennial Conference. Ithaca, New York, USA. June 2010.
67. **Craig BM**, Busschbach JJV. Revisiting United States Valuation of EQ-5D States [poster]. American Society of Health Economists (ASHE), Health, Healthcare & Behavior. 3rd Biennial Conference. Ithaca, New York, USA. June 2010.
68. Gu NY, Bond TG, **Craig BM**. Evaluating the measurement properties of an augmented EQ-5D with the inclusion of two single quality-of-life (QOL) indicators using the Medical Expenditure Panel Survey (MEPS). International Society for Pharmacoeconomics and Outcomes Research (ISPOR). 15th Annual Conference. Atlanta, Georgia, USA. May 17, 2010.
69. **Craig BM**. From a different angle: a novel approach to health valuation. EuroQol Group. 26th Plenary Meeting. Paris, France. September 2009.
70. **Craig BM**, Pickard S. Variability in QALY values for chronic conditions. EuroQol Group. 26th Plenary Meeting. Paris, France. September 2009.
71. Gu NY, Bond TG, Bjork S, **Craig BM**. (EQ-5D + VAS) x RASCH = HRQoL measure [poster]. EuroQol Group. 26th Plenary Meeting. Paris, France. September 2009.
72. **Craig BM**, Salomon J, Busschbach JJV. Re-estimation of United States Values for EQ-5D Health States [poster]. EuroQol Group. 26th Plenary Meeting. Paris, France. September 2009.
73. **Craig BM**, Busschbach JJV. Towards a more universal approach in health valuation [poster]. EuroQol Group. 26th Plenary Meeting. Paris, France. September 2009.
74. **Craig BM**. Weber's QALYs: DCE and TTO estimates are nearly identical. Health Economics Study Group (HESG). Sheffield, England, UK. July 23, 2009.

75. Abimbola T, **Craig BM**, Rollison DE, Kumar A, Giuliano A. Evidence synthesis for modeling the natural history of anal penile and oropharyngeal cancers [poster]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). 16th Annual Conference. Orlando, Florida, USA. May 18, 2009.
76. **Craig BM**, Abimbola T, Rollison DE, Kumar A, Giuliano A. Modeling Anal/Penile Cancer in HVP Vaccination [poster]. International Papillomavirus Society (IPVS). 25th Annual Conference. Malmö, Sweden. May 12, 2009.
77. **Craig BM**, Busschbach JJV, Oppe M. Revisiting the estimation of QALYs [workshop]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). 14th Annual Conference. Orlando, Florida, USA. May 18, 2009.
78. **Craig BM**, Oppe M. From a different angle: A novel approach to health valuation. Second Conjoint Analysis in Health Conference. Delray Beach, Florida, USA. March 26, 2009.
79. **Craig BM**, Renewing the War on Cancer [Plenary]. Association of Cancer Executives. 15th Annual Meeting. Sarasota, Florida, USA. February 16, 2009.
80. Gu NY, **Craig BM**, Doctor J. Diagnosing the EQ-5D items using the Rasch Models in a US Representative Sample. EuroQol Group. 25th Plenary Meeting. Lake Maggiore, Italy. September 2008.
81. Augustovski FA, Irazola VE, Velazquez AP, Gibbons L, **Craig BM**. Argentine Valuation of the EQ-5D Health States. EuroQol Group. 25th Plenary Meeting. Lake Maggiore, Italy. September 2008.
82. **Craig BM**, Busschbach JJV. Sample Size and State Selection Considerations in EQ-5D Valuation Studies. EuroQol Group. 25th Plenary Meeting. Lake Maggiore, Italy. September 2008.
83. **Craig BM**, Busschbach JJV, Salomon J. International Valuation Set for EQ-5D Health States [poster]. American Society of Health Economists (ASHE), Equity and Efficiency in Health and Healthcare. 2nd Biennial Conference. Durham, North Carolina, USA. June 2008.
84. **Craig BM**, Busschbach JJV, Salomon J. International Valuation Set for EQ-5D Health States [poster]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). 13th Annual Conference. Toronto, Ontario, Canada, May 2008.
85. **Craig BM**, Busschbach JJV, Salomon J. International Valuation Set for EQ-5D Health States. EuroQol Group. 24th Plenary Meeting. Der Haag, the Netherlands. September 2007.
86. **Craig BM**, Busschbach JJV, Salomon J. Ordinal valuation of health states: an eight country study [poster]. International Health Economics Association. (iHEA) 6th World Congress. Copenhagen, Denmark. July 2007.
87. **Craig BM**, Strassels S. Out-Of-Pocket Prices of Opioid Analgesics in the United States [poster]. International Society of Pharmacoeconomics and Outcomes Research (ISPOR). 12th Annual Conference. Washington, District of Columbia, USA. May 2007.
88. **Craig BM**, Busschbach JJV, Salomon J. Ordinal valuation of health states: a seven country study. EuroQol Group. 23rd Annual Conference. Barcelona, Spain. September 2006.
89. **Craig BM**, Deb P. A multimodal model of health care prices American Society of Health Economists (ASHE) Economics of Population Health. Inaugural Conference. Madison, Wisconsin, USA. June 2006.
90. **Craig BM**, Deb P. Out-of-pocket price of outpatient medications in the United States [poster]. International Society of Pharmacoeconomics and Outcomes Research (ISPOR). 11th Annual Conference. Philadelphia, Pennsylvania, USA. May 2006.
91. Ramachandran S, **Craig BM**, Coons SJ. Equivalence of paper and touch screen versions of the EQ-5D Visual Analog Scale (EQ-VAS) [poster]. International Society for Quality of Life Research. 12th Annual Conference. Washington, District of Columbia, USA. October 2005.
92. Salomon J, **Craig BM**. Estimating health state valuation functions based on ordinal ranking data: findings from a United States EQ-5D valuation study [poster]. International Health Economics Association (iHEA) 5th World Congress. Barcelona, Spain. July 2005.
93. **Craig BM**. Duration Dependence: a bridge between visual analog scale and time trade-off values [poster]. International Health Economics Association 5th World Congress. Barcelona, Spain. July 2005.
94. Chongpison Y, **Craig BM**, Coons SJ. Potential Impact of Health Status on Life Satisfaction and Quality of Life: A Pilot Study [poster]. International Society of Pharmacoeconomics and Outcomes Research (ISPOR.) 10th Annual Conference. Washington, District of Columbia, USA. May 2005.

95. Ramachandran S, **Craig BM**, Coons SJ. Equivalence of Paper and Touch Screen Versions of the EQ-5D Visual Analog Scale (EQ-VAS) [poster]. International Society of Pharmacoeconomics and Outcomes Research (ISPOR). 10th Annual Conference. Washington, District of Columbia, USA. May 2005.
96. Lundy JJ, **Craig BM**. The Impact of Medicare Part D on Economic Barriers to Prescription Medications among Beneficiaries with Multiple Sclerosis [poster]. International Society of Pharmacoeconomics and Outcomes Research (ISPOR). 10th Annual Conference. Washington, District of Columbia, USA. May 2005.
97. Mahmood MH, **Craig BM**, Ko Y, Armstrong E. Trends in the Prevalence of Inappropriate Prescribing among Elderly Medicare Beneficiaries, 1992-2001 [poster]. International Society of Pharmacoeconomics and Outcomes Research. (ISPOR). 10th Annual Conference. Washington, District of Columbia, USA. May 2005.
98. **Craig BM**, Ramachandran S, Coons SJ. Self-Assessed Health Status in the United States: EQ-5D Findings from the Medical Expenditure Panel Survey [poster]. International Society of Pharmacoeconomics and Outcomes Research (ISPOR). 10th Annual Conference. Washington, District of Columbia, USA. May 2005.
99. Herman P, **Craig BM**, Caspi O. Is Complementary and Alternative Medicine (CAM) Cost-Effective? A Systematic Review [poster]. Association for Women Faculty. Graduate Showcase of Women's Research. Tucson, Arizona, USA. March 2005.
100. Chongpison Y, **Craig BM**, Coons SJ. Potential Impact of Health Status on Life Satisfaction and Quality of Life: A Pilot Study [poster]. First Western Pharmacoeconomics Conference. Salt Lake City, Utah, USA. March 2005.
101. Ramachandran S, **Craig BM**, Coons SJ. Equivalence of Paper and Touch Screen Versions of the EQ-5D Visual Analog Scale (EQ-VAS) [poster]. Benefits and Challenges with ePRO: Outcomes and Endpoints as We Emerge from the Long Age of Paper. Drug Information Association Workshop. Arlington, Virginia, USA. April 2005.
102. **Craig BM**. Out-of-pocket Price, Prescription Medications and Seniors [poster]. Academy Health. 2003 Annual Research Meeting. Nashville, Tennessee, USA. June 2003.
103. **Craig BM**. Drug Coverage and the Out-of-pocket Price for Prescription Medications Among Elderly Medicare Beneficiaries [poster]. International Health Economics Association (iHEA) 4th World Congress. San Francisco, California, USA, June 2003.
104. Corden TE, Skoumal KS, Hubbard JM, Sheppard MA, **Craig BM**. Helmet Legislation Effect On Pediatric Bicycle-Related Head Injury Hospital Admissions in Wisconsin and the United States [poster]. 1st San Diego Pediatric Trauma Conference. San Diego, California, USA. October 2002.
105. **Craig BM**, Koc C. The Moral Hazard Effect of Insurance across Health Cohorts [poster]. International Health Economics Association (iHEA) 3rd World Congress. York, England. July 2001.
106. **Craig BM**, Koc C. The Moral Hazard Effect of Insurance across Health Cohorts [poster]. Academy for Health Services Research and Health Policy. Annual Meeting. Atlanta, Georgia, USA. June 2001.
107. **Craig BM**, Kind P. Logical Consistency and the Valuation of Health: An Analysis of US Survey Data. International Society of Pharmacoeconomics and Outcomes Research (ISPOR). 6th Annual Meeting. Arlington, Virginia, USA. May 2001.
108. **Craig BM**, Tseng DS. Dollars per Pound: A Cost-effectiveness Analysis of Obesity Treatments. Society for Medical Decision Making. Annual Meeting. Cincinnati, Ohio, USA. October 2000.
109. **Craig BM**, Koc C. The Gore Plan and the Utilization of Medical Services [poster]. Association for Health Services Research. Annual Meeting. Los Angeles, California, USA. June 2000.
110. **Craig BM**, Koc C. Insurance Endogeneity, Moral Hazard and the Demand for Health Care [poster]. Association for Health Services Research. Annual Meeting. Los Angeles, California, USA. June 2000.
111. **Craig BM**, Koc C. The Intensity of Moral Hazard across Medical Services. 4th Texas Camp Econometrics. Lake Texacoma, Texas, USA. February 1999.

Invited Podium Presentations

International:

1. Eliciting health preferences in small and heterogeneous groups: an introduction to preference paths and their kaizen tasks with three examples, Evidera, London, UK. February 2022.
2. Role Preferences in Medical Decision Making [Moderator], Health Preference Research Special Interest Group, International Health Economics Association, South Africa. January 2022.
3. A Guide to Observable Differences in Stated Preference Evidence, International Academy of Health Preference Research, Tampa, Florida, USA. December 2021.
4. Kaizen tasks in health preference research, Health Economics Research Centre, Department of Public Health, University of Oxford, Oxford, England, UK. November 2021.
5. Health Preference Research, Health Technology & Services Research, University of Twente, Enschede, The Netherlands, August 2021.
6. Preference paths & their kaizen tasks for health valuation, EuroQol Webinar Series, online, July 2021.
7. Extending choice analysis beyond logits, Seminar, Department of Economics, Curtin University, Perth, Western Australia, Australia, November 2020.
8. Health Preference Research: past, present and possible future, Erasmus Choice Modelling Centre, Erasmus University, Rotterdam, the Netherlands, March 2019.
9. Health Preference Research: past, present and possible future, Health Economics Research Centre, Department of Public Health, University of Oxford, Oxford, England, UK. March 2019.
10. Health Preference Research: past, present and possible future, Centre for Health Economics in London, London School of Hygiene and Tropical Medicine, UK. March 2019.
11. Experience-based methods for DCE designs. Symposium on DCE Design. International Academy of Health Preference Research. 8th Meeting. Hobart, Australia. September 2018.
12. Psychometric versus Preference-based health-related quality of life summary measures (with Ronald Hays), Debating Hot Topics in HRQOL Research Webinar Series, International Society for Quality of Life Research (ISOQOL) Online Education. December 2017
13. Conceptual Frameworks, EuroQol Group, 2nd EuroQol Academy Meeting. Noordwijk aan Zee, the Netherlands. March 2017.
14. Choice Defines Value: How To Analyse And Disseminate Evidence On The Importance Of Multiple Criteria From Multiple Perspectives To Inform An Appraisal Process In Health Technology Assessment, International Society for Pharmacoeconomics and Outcomes Research, 19th Annual European Congress, Austria Centre, Vienna, Austria, November 2016.
15. Diminishing Marginal Returns of Quality Adjusted Lifespan, Séminaires départementaux, Faculté d'administration, Université de Sherbrooke, Sherbrooke, Quebec, Canada. May 18, 2016 9:00-10:00AM.
16. The Value of Adverse Event Relief from the Perspective of Cancer Patients, Conférence du Centre de Recherche, Université de Sherbrooke, Sherbrooke, Quebec, Canada. May 17, 2016 12:00-1:00PM.
17. Health Preference Research: Enhancing the Relevance of QOL Evidence [Symposium]. International Society for Quality of Life Research, 22nd Annual Conference, Vancouver, British Columbia, Canada. October 23, 2015 11:20-12:35PM.
18. The Demand for Health: Cancer, Menopause, and ADHD, Centre for Health Economics Research and Evaluation, University of Technology, Sydney, Sydney, New South Wales, Australia, September 28, 2015.
19. 2015 Academy Webinar, International Academy of Health Preference Research Foundation, Inc., Tampa, Florida, USA, February 2015.
20. Challenges in the Valuation of Health: Men, Women and Children, Centre for Health Economics, Monash University, Clayton, Victoria, Australia, November 2014.
21. Choice Defines Value: Interpretation of Criteria Weights in Multi-Criteria Decision Making, International Society for Pharmacoeconomics and Outcomes Research, 17th Annual European Congress, Amsterdam RAI, Amsterdam, The Netherlands, November 2014.
22. Benefit Assessment and Patient Preferences, Bundesverband Managed Care e.V., Berlin, Germany, October, 2014.

23. Choice Defines Value: Turning preferences of multiple stakeholders into evidence for health care decision making, International Society for Pharmacoeconomics and Outcomes Research, 21st Annual Meeting, Palais des Congrès de Montréal, Montreal, Quebec, Canada, June 2014 (workshop).
24. Choice Defines Value: New Approaches to evaluating multiple treatment attributes and health outcomes, International Society for Pharmacoeconomics and Outcomes Research, 20th Annual Meeting, New Orleans, Louisiana, USA, May 2013 (workshop).
25. Discrete Choice and Health Valuation, Bundesverband Managed Care e.V., Berlin, Germany, November 2012.
26. Choice Defines Value: New Approaches to estimating QALYs, HYE, and efficiency frontiers, International Society for Pharmacoeconomics and Outcomes Research, 15th Annual European Congress, Berlin, Germany, November 6, 2012 (workshop).
27. US valuation of child health outcomes, Youth Taskforce, EuroQol Group, Amsterdam, the Netherlands, May 2012.
28. How to translate PROs into Irish QALYs using the internet, Irish National Centre for Pharmacoeconomics, Trinity College Dublin, Dublin, Ireland. July 2011.
29. Incorporating Patient Reported Outcome Measures into US Comparative Effectiveness Research, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, Scotland, UK, June 2011
30. How to translate PRO into QALYs using the internet, Centre for Health Economics, University of York, York, England, UK. June 2009.
31. Online Technological Constraints in Experimental Health Economics, Health Economics Research Unit, University of Aberdeen, Aberdeen, Scotland, UK, June 2011.
32. The Emperor's New Clothes: revisiting QALY estimation, Health Economics Research Centre, Department of Public Health, University of Oxford, Oxford, England, UK. July 2009.
33. Towards a more universal approach in health valuation, Centre for Health Economics, University of York, York, England, UK. July 2009.
34. The Emperor is Naked: Revisiting Quality-adjusted Life Year (QALY) Estimation, Irish National Centre for Pharmacoeconomics, Trinity College Dublin, Dublin, Ireland. July 2009.
35. All models are wrong, but some are useful: the case of quality-adjusted life years (QALYs), Health Economics, School of Health and Population Sciences, University of Birmingham, Birmingham, England, UK. July 2009.
36. Revisiting UK QALY Estimates, Institute of Health and Society, Newcastle University, Newcastle, England, UK. July 2009.
37. Revisiting the UK EQ-5D and SF-6D QALY Estimates, Institute of Health Sciences, University of Leeds, Leeds, England, UK. July 2009.
38. Revisiting QALY Estimation, Health Economics and Decision Science (HEDS), University of Sheffield, Sheffield, England, UK. June 2009.
39. The Influence of Benjamin Franklin's Prudential Algebra on Public Health Policy, Health Economics and Decision Science (HEDS), University of Sheffield, Sheffield, England, UK. June 2009.
40. Episodic Random Utility Model for QALY Estimation. Health Economics and Decision Science (HEDS), University of Sheffield, Sheffield, England, UK. October 2008.
41. Valuing EQ- 5D with Time Trade-off for the Polish Population. 25th Plenary Meeting of the EuroQol Group, Lake Maggiore, Italy. September 2008.
42. Valuing Health: An Eight Country Study. Department of Community Health and Epidemiology Seminar, Dalhousie University, Halifax, Nova Scotia, Canada. October 2007.

National:

1. US COVID-19 Vaccination Preferences: 2020 Hindsight, Arkansas Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, Arkansas, May 13, 2021

2. The Future of Health Preferences in Regulatory and Clinical Decisions, Center for Devices and Radiological Health, U.S. Food and Drug Administration. September 2017
3. The Future of Health Preferences in Regulatory and Clinical Decisions, Arkansas Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, Arkansas, May 5, 2017
4. The Future of Health Preferences in Regulatory and Clinical Decisions, Patient Voice Seminar, Duke University, Durham, North Carolina, February 14, 2017
5. The Future of Health Preferences in Regulatory and Clinical Decisions, University of South Carolina, Columbia, South Carolina, 1 February 1, 2017.
6. Preferences of Patients with Cancer, Healthcare Delivery Research Program, National Cancer Institute, Rockville, Maryland, USA. November 2015
7. Challenges in Health Preference Research: Men, Women, and Children, School of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA. March 2015
8. Challenges in Health Preference Research: Men, Women, and Children, Washington University in St. Louis, St. Louis, Missouri, USA. March 2015
9. Preference-based measurement strategies for PROMIS, 5th Psychometric Summit, Crystal City Marriott, Arlington, Virginia, USA. June 2014.
10. Health Valuation for Comparative Effectiveness Research. Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, California, USA. October 2013.
11. Cost-effectiveness of a Mindfulness Based Stress Reduction Program for Improving Quality of Life in Breast Cancer Survivors: Results from a Randomized Control Trial. Economic Supplement Meeting, Survivorship Office, National Cancer Institute. Bethesda, Maryland, USA. September 2013
12. Between Chocolates and Cars: a re-interpretation of conventional choice models. Brown Bag Lunch Series, Health Preference Assessment, RTI Health Solutions, RTI International, Research Triangle Park, North Carolina, USA. May 2013.
13. Health Valuation for Comparative Effectiveness Research. School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA. April 2013.
14. Expressing the value of improved health-related quality of life (HRQOL) in terms of survival. Health Economics Statistics, Merck & Co. Inc., North Wales, Pennsylvania, USA. January 2013.
15. Enhancing Patient-Reported Outcomes for Comparative Effectiveness Research. Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. February 2012.
16. Translating cancer outcomes into QALYs using experimental economics. Cancer Outcomes/ICISS Seminar, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill. Chapel Hill, North Carolina, USA. October 2011.
17. The Next Generation of Quality-Adjusted Life Years for CER. Comparative Effectiveness Research Seminar, Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA. October 2011.
18. Methods in Online Discrete Choice Experiments. Brown Bag Lunch Series, Health Preference Assessment, RTI Health Solutions, RTI International, Research Triangle Park, North Carolina, USA. October 2011.
19. Enhancing Patient-Reported Outcomes for Comparative Effectiveness Research. Yale University, New Haven, Connecticut, USA. May 2011.
20. Enhancing Patient-Reported Outcomes for Comparative Effectiveness Research. University of Michigan, New Haven, Connecticut, USA. May 2011.
21. Understanding how choices reveal the value of health. Colorado School of Public Health, Denver, Colorado, USA. January 5, 2011.
22. Cumulating Health Outcomes in Comparative Effectiveness (CHOICE) Research. Virginia Commonwealth University, Richmond, Virginia, USA. October 14, 2010.
23. Comparing Health Outcomes in Comparative Effectiveness (CHOICE) Research: Do preferences matter? University of California, Los Angeles, Los Angeles, California, USA. July 13, 2010.

24. Valuing Health and Longevity for Public Policy. Institute for Child Health Policy. University of Florida. Gainesville, Florida, USA. January 14, 2009.
25. Oncopolitics and Policy. Researchers in Cancer Economics (RICE) Working Group Meeting. Principles and Practice of Cancer Prevention and Control Course. National Cancer Institute. Bethesda, Maryland, USA. July 21, 2008.
26. Health Technology Assessment in Cancer. Researchers in Cancer Economics (RICE) Working Group Meeting. Principles and Practice of Cancer Prevention and Control Course. National Cancer Institute. Bethesda, Maryland, USA. July 17, 2008.
27. Overview of Cancer Economics. Researchers in Cancer Economics (RICE) Working Group Meeting. Principles and Practice of Cancer Prevention and Control Course. National Cancer Institute. Bethesda, Maryland, USA. July 14, 2008.
28. Average versus Quantile Treatment Effects: Estimating Differential Outcomes between Alternative Treatment Therapies by Bijan J. Borah. American Society of Health Economists, Equity and Efficiency in Health and Healthcare. 2nd Biennial Conference. Durham, North Carolina, USA. June 23, 2008. [Invited discussant].
29. Does the Promotion of Community-Level Social Capital Reduce Obesity Risk? by Jangho Yoon, University of California at Berkeley. American Society of Health Economists, Equity and Efficiency in Health and Healthcare. 2nd Biennial Conference. Durham, North Carolina, USA. June 24, 2008. [Invited discussant].
30. Does Mothers' Willingness To Pay for Children's Health Differ from Fathers? by Soyeon Guh, University of North Carolina at Chapel Hill. American Society of Health Economists, Equity and Efficiency in Health and Healthcare. 2nd Biennial Conference. Durham, North Carolina, USA. June 23, 2008. [Invited discussant].
31. Research on Medicare Part D and Reimbursement Policies II. International Society for Pharmacoeconomics and Outcomes Research. 15th Annual Conference. Toronto, Ontario, Canada. May 5, 2008. [Session moderator].
32. Estimating the Welfare Effects of Alternative Liability Regimes by Eric Sun and Tomas Philipson. Annual Health Economics Conference. Phoenix, Arizona, USA. March 2007. [Invited discussant].
33. Gamma Mixture Models and Their Use in Price and Expenditure Estimations. University of Southern California School of Pharmacy. Los Angeles, California, USA. September 2006.
34. Price Shock: a common side effect of appropriate care. Mayo Clinic. Rochester, Minnesota, USA. July 2006.
35. What do we pay for appropriate care? Division of Social and Administrative Sciences, School of Pharmacy, University of Wisconsin-Madison. Madison, Wisconsin, USA. June 2006.
36. Instrumental Variables in Addressing Selection Bias in Observational Studies. University of Arkansas, College of Pharmacy. Little Rock, Arkansas, USA. April 2006.
37. A model of health care prices. Pharmaceutical Economics Group, School of Pharmacy, University of Iowa. Iowa City, Iowa, USA. April 2006.
38. A model of health care prices. Department of Pharmacy Administration, College of Pharmacy, University of Illinois at Chicago. Chicago, Illinois, USA. March 2006.
39. A model of health care prices. Department of Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland. Baltimore, Maryland, USA. November 2005.
40. A model of health care prices. Merck & Co., Inc. Blue Bell, Pennsylvania, USA. November 2005.
41. A model of health care prices. Division of General Internal Medicine, School of Medicine, University of Pennsylvania. Philadelphia, Pennsylvania, USA. November 2005.
42. A model of health care prices. Department of Health Policy and Administration, School of Public Health, University of North Carolina at Chapel Hill. Chapel Hill, North Carolina, USA. November 2005.
43. Econometric Models of Expenditure. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Webcast. USA. October 2005.
44. Research Using the Medicare Current Beneficiary Survey. Sonderegger Research Center, School of Pharmacy, University of Wisconsin – Madison. Madison, Wisconsin, USA. June 2005.

Regional:

1. Health Preferences of Patients with Cancer, Grand Rounds in Population Sciences, Moffitt Cancer Center, Tampa, Florida, USA, August 13, 2015
2. The Value Floridians with Metastatic Prostate Cancer Place on Quality of Life: A Patient-centered Pilot Study, Florida Prostate Cancer Research Symposium, Orlando, Florida, USA, May 2, 2015
3. Genitourinary Cancer Outcomes Research (GCOR) and Valuation Studies, the Movember Foundation, Moffitt Cancer Center, Tampa, Florida, USA, March 2, 2015
4. Health Preferences of Puerto Rico. U54 Ponce School of Medicine-Moffitt Cancer Center Partnership, Moffitt Cancer Center, Tampa, Florida, USA, August 27, 2014
5. Health Preference Research: an Introduction to Craig Lab, Moffitt Business Center, Moffitt Cancer Center, Tampa, Florida, June 26, 2014
6. Health Preference Research: an Introduction to Craig Lab, Moffitt Foundation, Moffitt Cancer Center, Tampa, Florida, February 14, 2014
7. Difficult Decisions in Health Care: Genetic Counseling and Women's Health Preferences. Health Occupations Student Association, University of South Florida, Tampa, Florida, USA, March 21, 2013.
8. Enhancing Health Outcomes Measures for Comparative Effectiveness Research. 2012 Moffitt Scientific Symposium, Moffitt Cancer Center, Tampa, Florida, USA, May 10, 2012.
9. Innovation Section Workshop with Vani Nath Simmons. Health Outcomes and Behavior, Moffitt Cancer Center. Tampa, Florida, USA. Nov 4, 2011.
10. Smoking Research Collaborations in Pragmatic Online Experiments, Tobacco Research and Intervention Program, Moffitt Cancer Center. Tampa, Florida, USA. Sept 9, 2011.
11. Online Experimental Techniques for Social Science Research Workshop. Moffitt Cancer Center. Tampa, Florida, USA. May 5, 2011.
12. Economics Research at Moffitt Cancer Center. Clinical Fellows. Moffitt Cancer Center. Tampa, Florida, USA. September 13, 2010.
13. Simulating the contributions of a biorepository in a phase-2 clinical trial: a value of information analysis. Biostatistics Core. Moffitt Cancer Center. Tampa, Florida, USA. July 27, 2010.
14. Comparing Health Outcomes in Comparative Effectiveness Research: Do preferences matter? Grand Rounds. Moffitt Cancer Center. Tampa, Florida, USA. June 4, 2010.
15. The Arctangent Model in Conjoint Analysis. Biostatistics Core. Moffitt Cancer Center. Tampa, Florida, USA. May 10, 2010.
16. Participation of Cancer Patients in Clinical Trials. Moffitt Scientific Retreat. Moffitt Cancer Center. Tampa, Florida, USA. March 6, 2009.
17. Renewing the War on Cancer, Hematology-Oncology Fellows Seminar. Moffitt Cancer Center. Tampa, Florida, USA. February 11, 2009.
18. Directional Statistics in Health Econometrics. Health Economics Seminar. University of South Florida. Tampa, Florida, USA. November 21, 2008.
19. Renewing the War on Cancer. Pinellas Professional Partners. Moffitt Foundation. Tampa, Florida, USA. October 2, 2008.
20. The Estimation of Health Preferences. Biostatistics Core. Moffitt Cancer Center. Tampa, Florida, USA. September 26, 2008.
21. Cancer Economics Database (CED). Moffitt Cancer Center. Tampa, Florida, USA. May 22, 2008.
22. Valuing Health. Evidence-based Medicine and Decision Sciences Section. Moffitt Cancer Center. Tampa, FL. May 2008.
23. Valuing Health. Health Economics Seminar. University of South Florida. Tampa, Florida, USA. April 2008.
24. Assessment of Evaluative Technologies. Evidence-based Medicine and Decision Sciences Section. Moffitt Cancer Center. Tampa, Florida, USA. March 2008.
25. Assessment of Evaluative Technologies. Xcenda. Palm Harbor, Florida, USA. March 2008.

26. Introduction to Cancer Economic Evaluations. Health Outcomes & Behavior Meeting. Moffitt Cancer Center. Tampa, Florida, USA. February 2008.
27. Out-of-pocket prices for prescription medications: an application of mixture models. Health Economics Seminar. University of South Florida. Tampa, Florida, USA. February 2008.
28. Economics Research at Moffitt Cancer Center. Senior Adult Oncology Research Meeting. Moffitt Cancer Center. Tampa, Florida, USA. January 2008.
29. How it Might Reshape Oncology. Paul P. Carbone Comprehensive Cancer Center Grand Rounds. University of Wisconsin. Madison, Wisconsin, USA. October 2007. The National Cancer Act of 2007.
30. Do seniors get the medications prescribed for them and what do they pay? January Conference. The Center for Health Outcomes and Pharmacoeconomic Research. Tucson, Arizona, USA. January 2006.
31. Overview of Cancer Economics. January Conference. The Center for Health Outcomes and Pharmacoeconomic Research. Tucson, Arizona, USA. January 2005.
32. Measuring Economic Outcomes of Cancer. Cancer Prevention and Control Program Grand Rounds, Arizona Cancer Center. Tucson, Arizona, USA. November 2003.

Other Education

April 2022	Intensive Spanish , FU International Academy, Puerto de la Cruz, Tenerife, Spain.
June 2012	Content Validity of PRO, ClinRO and ObsRO Assessments , Donald L. Patrick, Mona L. Martin, Chad Gwaltney, Nancy Kline Leidy, Pre-Conference Workshop, The International Society for Pharmacoeconomics and Outcomes Research, 17th Annual Conference, Washington, District of Columbia, USA.
October 2010	Choice-based Conjoint , Aaron Hill and Brian McEwan, Sawtooth Software Pre-Conference Workshop, Newport Beach, California, USA.
October 2010	Applying Best-Worst Scaling in Health Care , Terry Flynn and Jordan Louviere, Sawtooth Software Pre-Conference Workshop, Newport Beach, California, USA.
May 2010	Patient-Reported Outcomes – Item Response Theory , Bryce Reeve, Pre-Conference Workshop, The International Society for Pharmacoeconomics and Outcomes Research, 15th Annual Conference, Atlanta, Georgia, USA.
Summer 2008	Molecular Prevention Course , National Cancer Institute, Bethesda, Maryland, USA.
Summer 2008	The Principles and Practice of Cancer Prevention and Control Course , National Cancer Institute, Bethesda, Maryland, USA.
May 2008	Patient-Reported Outcomes - Item Response Theory , Lori McLeod, Cheryl Hill, Pre-Conference Workshop, The International Society for Pharmacoeconomics and Outcomes Research, 13th Annual Conference, Toronto, Ontario, Canada.
Spring 2008	Hematology-Oncology Fellowship Seminars and Journal Club , Kenneth Zuckerman, Moffitt Cancer Center, Tampa, Florida, USA.
Fall 2007	Medical Oncology Fellowship Seminars and Journal Club , James Stewart, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Spring 2007	Clinical Nutrition , Gail Underbakke, Patrick McBride, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Spring 2007	Principles of Human Physiology , Richard Moss, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Fall 2006	Integrated Medical Anatomy , Karen Krabbenhoft, Edward Schultz, Gary Lyons, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Spring 2006	Patient Registries: Overview and Application , Jeff Trotter, ISPOR Workshop, Philadelphia, Pennsylvania, USA.
Spring 2006	Cost-effectiveness Analysis Alongside Clinical Trials , Scott Ramsey, Richard Willke, ISPOR Workshop, Philadelphia, Pennsylvania, USA.

July 2005	Health Econometrics of Health Cost , Expenditure and Utilization Data, Partha Deb, Willard Manning, Edward Norton, iHEA World Congress, Barcelona, Spain.
July 2005	Risk Adjustment and Predictive Modeling , Randel Ellis, iHEA World Congress, Barcelona, Spain.
July 2005	Econometric Methods for Health Policy Analysis Using Non-Experimental Data , Joseph Terza, iHEA World Congress, Barcelona, Spain.
May 2005	CMS 301: Using SEER/Medicare Data for Research , ResDAC, Minneapolis, Minnesota, USA.
Spring 2005	Topics in Econometrics (ECON 696E) , Keisuke Hirano, Department of Economics, Eller College of Management, The University of Arizona, Tucson, Arizona, USA.
Spring 2005	Causal Inference and Program Evaluation (ECON 696F) , Keisuke Hirano, Department of Economics, Eller College of Management, University of Arizona, Tucson, Arizona, USA.
Spring 2004	Experimental Economics II (ECON 696B) , Martin Duwenberg, Department of Economics, Eller College of Management, University of Arizona, Tucson, Arizona, USA.
July 2002	MiniMedical School for Social Scientists and Demography, Economics, and Epidemiology of Aging Conference , RAND Summer Institute, Santa Monica, California, USA.
July 2001	Medicare Current Beneficiary Survey Workshop , ResDAC, Minneapolis, Minnesota, USA.
September 2000	CMS 101: Introduction to the use of Medicare claims data for research , ResDAC, Minneapolis, Minnesota, USA.